https://www.proactiveinvestors.com Proactiveinvestors RSS feed en Wed, 17 Oct 2018 19:49:57 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Pressure BioSciences accelerates development of its Ultra Shear Technology pressure-based platform to target new markets ]]> https://www.proactiveinvestors.com/companies/news/206321/pressure-biosciences-accelerates-development-of-its-ultra-shear-technology-pressure-based-platform-to-target-new-markets-206321.html Pressure BioSciences Inc (OTCQB:PBIO) announced Wednesday that it will commit significant financial and operational resources to accelerate the development of the company’s pressure-based patented platform, Ultra Sheer Technology, which gives milk and beverages a longer shelf life.

The South Easton, Massachusetts, company already holds two patents for Ultra Sheer Technology, which applies high-pressure levels greater than 20,000 pounds per square inch. The technology allows companies to extend the life of milk, and healthier drinks and juices, by reducing heat exposure in the preservation process through a combined application of elevated pressure and controlled times and temperatures.

Ultra Sheer Technology also utilizes high pressure to create intense, momentary liquid shearing forces at controlled temperatures that result in affordable and scalable homogenization of liquids, creams and gels. The technology creates nano-scale emulsion mixtures of otherwise immiscible fluids like oils in water that results in stable homogenized products called nanoemulsions.

For many oil-based nutritional and medical products, nanoemulsions can offer superior water solubility and increased bio-availability for improved absorption via oral or topical administration. As a result, the technology has wide potential uses in the pharmaceutical, industrial ink, retail and cosmetics industry.

"Nanoemulsions have been shown to exhibit improved absorption, higher bioavailability, and greater stability, while often requiring lower levels of stabilizing chemicals (emulsifiers) than macroemulsion products. Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide,” said Dr Edmund Ting, senior vice president of engineering for Pressure BioSciences.

READ: Pressure BioSciences developing breakthrough processing method for shelf-stable milk, dairy products

“Cost-effective scale-up of nanoemulsion processing at a commercial level has been historically challenging, but we believe that Pressure BioSciences' innovative process design patents provide the key to commercial success for nanoemulsion products," he added.

The company said there are “significant opportunities” for economically-scalable nanoemulsion products worldwide such as premium dairy products and salad dressings.  

"These opportunities become particularly exciting in high-value products like lubricants, cosmetics and nutraceuticals,” said Dr Nate Lawrence, vice president of marketing and sales at Pressure BioSciences.

Partnership with Ohio State

In July, Pressure BioSciences announced its collaboration with researchers at Ohio State University to work on this new method of making sure milk and juice are free of pathogens and chemical preservatives and will not require refrigerated transport. The goal of this working venture was to bring Ultra Sheer Technology to market.

The collaborative project is funded by a US$891,000 grant from the US Department of Agriculture. Ohio State has granted Pressure BioSciences a US$318,000 sub-contract to build a working benchtop instrument and a pilot plant floor model Ultra Shear Technology machine.

"We have committed approximately 2,000 sq feet of recently acquired space to our Ultra Shear Technology platform development and nanoemulsions commercialization program,” said Pressure BioSciences CEO Richard T. Schumacher.

“We view this as an extraordinary opportunity that offers a range of major new market segments for us. We have instructed our engineering and R&D personnel to finalize the development of our first-generation UST instrument and to make the generation of proof-of-principle nanoemulsion data for multiple product areas their top priority. We have also reallocated significant time and resources from several staff members to the UST platform development program," added the Harvard Medical School-trained serial entrepreneur.

The CEO said the company was “accelerating discussions” with multiple US and Canadian companies, academic organizations, and government agencies which have expressed interest in collaborating with Pressure BioSciences to access its technology.

READ: Pressure BioSciences' ultra-high pressure products featured in Chicago food tech conference

“We are on course to establish collaborative development projects with multiple companies and research groups addressing different product and market opportunities. These programs should lead to revenue-generating products in the near future. We believe there are many industries that can benefit from UST-produced nanoemulsions and that this can be an area of rapid and sizeable growth for Pressure BioSciences moving forward," said Schumacher.

Commencing commercial operations in 2007, Pressure BioSciences is a leader in developing high-pressure-based technologies, platforms and services for the life sciences market worldwide.

The company recently reported second-quarter results that marked a tenth consecutive quarterly jump in products and services revenue, thanks to booming sales of lab instruments which utilize pressure to control bio-molecular interactions. For the quarter ended June 2018, the company reported an 18% jump in total revenue to US$638,800 compared to US$540,400 for the same period in 2017.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

 

]]>
Wed, 03 Oct 2018 10:40:00 -0400 https://www.proactiveinvestors.com/companies/news/206321/pressure-biosciences-accelerates-development-of-its-ultra-shear-technology-pressure-based-platform-to-target-new-markets-206321.html
<![CDATA[News - Pressure BioSciences' ultra-high pressure products featured in Chicago food tech conference ]]> https://www.proactiveinvestors.com/companies/news/205353/pressure-biosciences-ultra-high-pressure-products-featured-in-chicago-food-tech-conference-205353.html Pressure BioSciences Inc (OTCQB: PBIO) announced on Thursday that its ultra-high pressure product line of instruments, methods, and technology platforms was prominently featured at the recent Institute of Food Technologists annual meeting in Chicago.

The company's Ultra Shear Technology platform, particularly its US Department of Agriculture-funded collaborative program with Ohio State University's College of Food, Agricultural, and Environmental Sciences, was the focus of much discussion during the four-day conference, the company said.

READ: Pressure BioSciences shares jump on sales of first two HUB 880 Explorer research instruments

"My research group presented on the effects of high hydrostatic pressure on the inactivation of foodborne pathogens of major public health concern, such as E. coli, salmonella, cronobacter, and listeria," Aliyar Fouladkhah, assistant professor and Director of the Public Health Microbiology Laboratory at Tennessee State University, said.

"We believe the data we presented, much of it generated with PBI's high pressure-based instruments, will assist food safety researchers and stakeholders worldwide as they consider the use of pressure-based interventions for their microbiological studies." 

The research programs at the Fouladkhah and PHM Laboratories at TSU primarily focus on the development of methods to improve microbial safety of various food products.

Shares of Pressure BioSciences were we flat at US$3.50 in Thursday morning trading.

READ: Pressure BioSciences posts record 2Q product and services revenue, lowers operating expenses

The IFT has been advancing the application of science across the global food production and supply system since 1939. Its annual meeting is the world's largest yearly food science event, with over 20,000 food industry professionals in attendance.

Recent enhancements in the commercial feasibility of high-pressure processing (HPP) have been pivotal in the development of new methods for ensuring food safety, while preserving important sensory experience and quality factors. 

Fouladkhah said PBI's Ultra-Shear Technology (UST) platform offers the potential to greatly benefit the food and many other industries, as it could conceivably inactivate the most resistant pathogenic organisms in (the) food matrix, resulting in safer and more stable products."

Last week, the company announced the sale of the first two instruments from its newest line of high-pressure based instrument systems which would help raise productivity while cutting production costs.

Pressure BioSciences is a leader in the development and sale of pressure-based solutions for the worldwide life sciences industry.

]]>
Thu, 20 Sep 2018 09:57:00 -0400 https://www.proactiveinvestors.com/companies/news/205353/pressure-biosciences-ultra-high-pressure-products-featured-in-chicago-food-tech-conference-205353.html
<![CDATA[News - Pressure BioSciences shares jump on sales of first two HUB 880 Explorer research instruments ]]> https://www.proactiveinvestors.com/companies/news/204861/pressure-biosciences-shares-jump-on-sales-of-first-two-hub-880-explorer-research-instruments-204861.html Pressure BioSciences Inc (OTCQB:PBIO) announced Thursday that it has sold the first two research instruments from its newest line of high-pressure based systems, the HUB880 Explorer.

With its ability to reach higher pressure levels and accept larger sample sizes, the HUB880 Explorer allows scientists to study the mechanisms by which pressure inactivates food pathogens and organisms that cause food to spoil, which should improve the processing of food.

Shares climbed 14% in midday trading to US$4.00.

Read: Pressure BioSciences receives a US patent for a new high-pressure flow-through microfluidic sample preparation device

“Because of this, we believe the HUB880 Explorer has the potential to add significantly to our revenue base in the foreseeable future,” said Dr Nate Lawrence, Pressure Bio’s vice-president of marketing and sales.

Pressure Bio’s first customer to buy a HUB880 Explorer machine is a leading research institute in Japan which is conducting research and development on agriculture and food. The institute intends to use the HUB 880 Explorer to study the impact of high pressure on food processing as well as on food-borne pathogens.

Its second machine, meanwhile, was purchased by the Public Health Microbiology (PHM) Laboratory at Tennessee State University, which will use the technology to conduct research to better understand environmental and enteric pathogens as well as spoilage organisms.

One out of six Americans experiences illnesses from these pathogens every year, according to the PHM laboratory, leading to about 128,000 hospitalizations in the US.

Read: Pressure BioSciences posts record 2Q product and services revenue, lowers operating expenses

Dr Aliyar Fouladkhah, an assistant professor at Tennessee State and the director of the PHM laboratory, reports that his team has used PBI’s pressure-based instruments for several years to produce research on foodborne pathogens and food quality for publication.

Commencing commercial operations in 2007, Pressure BioSciences, which is based in South Easton, Massachusetts, is a leader in developing high-pressure-based technologies, platforms and services for the life sciences market worldwide.

The company recently reported second-quarter results that marked a tenth consecutive quarterly jump in products and services revenue, thanks to booming sales of lab instruments which utilize pressure to control bio-molecular interactions. For the quarter ended June 2018, the company reported an 18% jump in total revenue to US$638,800 compared to US$540,400 for the same period in 2017.

]]>
Thu, 13 Sep 2018 10:52:00 -0400 https://www.proactiveinvestors.com/companies/news/204861/pressure-biosciences-shares-jump-on-sales-of-first-two-hub-880-explorer-research-instruments-204861.html
<![CDATA[News - Pressure BioSciences receives a US patent for a new high-pressure flow-through microfluidic sample preparation device ]]> https://www.proactiveinvestors.com/companies/news/203904/pressure-biosciences-receives-a-us-patent-for-a-new-high-pressure-flow-through-microfluidic-sample-preparation-device-203904.html Pressure BioSciences Inc (OTCQB:PBIO) announced Thursday that it had received a key US patent for a novel high-pressure flow-through microfluidic sample preparation device.

The company was given US Patent No. 9995661 called ''Flow-through High Hydrostatic Pressure Microfluidic Sample Preparation Device and Related Methods Therefor.'' With the new patent, the company’s intellectual property estate expands to 21 patents.

On a separate note, the company also holds two patents for Ultra Sheer Technology, which applies high-pressure levels greater than 20,000 pounds per square inch. The technology allows companies to extend the life of milk, and healthier drinks and juices, by reducing heat exposure in the preservation process through a combined application of elevated pressure and controlled times and temperatures.

The South Easton, Massachusetts-based company is a leader in high-pressure-based technologies, platforms and services to the life-sciences market worldwide.

''This invention covers key elements of our plans for developing automated, hands-free sample handling for the next generation of our high-pressure sample preparation platform technologies,” said Alexander Lazarev, vice president of R&D, at Pressure Biosciences.

READ: Pressure BioSciences posts record 2Q product and services revenue, lowers operating expenses

Lazarev said the invention enabled a “unique capability” for “maintaining high pressure in a flow-through format,” rather than current batch processing. The R&D chief said this could spur the development of new, automated “continuous process monitoring tools” for the life sciences industry

“We believe this novel flow-through concept offers critical enablement for future system design strategies for epitope characterization, an emerging area in development and production of biotherapeutics that could revolutionize personalized therapy for numerous medical conditions, including autoimmune diseases and a variety of rare medical disorders,” said Lazarev.

Pressure BioSciences develops pressure cycling technology (PCT) solutions and hundreds of labs utilize the company's pressure-based systems to extract proteins carefully from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

Pressure BioScience’s Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one of the assets Pressure BioSciences acquired as part of its acquisition of all the assets of BaroFold Inc last December.

''We believe that the hands-free, automated workflow enabled by this invention will allow for the development of valuable enhancements in efficiencies, throughput and contamination avoidance for our instrument and consumable product lines,” said CEO Richard T. Schumacher.

READ: Pressure BioSciences expects to win additional patents for its Ultra Sheer Technology pressure-based platform

“We also believe this invention will accelerate our expansion into larger scale applications and users in multiple business segments. Growth in these additional areas should further expand market acceptance and recognition for our innovative and enabling pressure-based platform technologies and spur concomitant growth in revenue,'' he added.

The company recently reported second-quarter results that marked a tenth consecutive quarterly jump in products and services revenue, thanks to booming sales of lab instruments which utilize pressure to control bio-molecular interactions. For the quarter ended June 2018, the company reported an 18% jump in total revenue to US$638,800 compared to US$540,400 for the same period in 2017.

Shares added 3.20% to US$3.55.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

 

]]>
Thu, 30 Aug 2018 09:37:00 -0400 https://www.proactiveinvestors.com/companies/news/203904/pressure-biosciences-receives-a-us-patent-for-a-new-high-pressure-flow-through-microfluidic-sample-preparation-device-203904.html
<![CDATA[News - Pressure BioSciences posts record 2Q product and services revenue, lowers operating expenses ]]> https://www.proactiveinvestors.com/companies/news/202979/pressure-biosciences-posts-record-2q-product-and-services-revenue-lowers-operating-expenses-202979.html Pressure BioSciences Inc (OTCQB:PBIO) posted second-quarter results Wednesday that marked a tenth consecutive quarterly jump in products and services revenue, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

Significantly, the company also decreased operating expenses by 24% through savings in advertising and PR costs.

For the quarter ended June 2018, the South Easton, Massachusetts-based company reported an 18% jump in total revenue to US$638,800 compared to US$540,400 for the same period in 2017.

This increase was driven by a double-digit growth in products and services revenue to US$618,400 for the quarter compared to US$480,400 a year ago. Sales of instruments also jumped 14% to US$397,000 on a year-over-year basis. During the quarter, Pressure BioSciences also secured a US$318,000 contract from Ohio State University for the development of the company’s high-pressure Ultra Shear Technology.

"Quarterly gross profit margins increased by double digits year-over-year. During the quarter, operating loss decreased by US$283,400 (24%), as our focus on reducing expenditures in investor and public relations, advertising, and non-essential corporate services began to pay dividends. Importantly, while we were posting revenue increases and operating expense decreases, we were also successful in completing a critical objective of converting US$13.6mln of debt into equity," said Pressure BioSciences CFO Joseph L Damasio.

BIG PICTURE: Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share

Shares of Pressure BioSciences rose 1.3% to US$3.95 Wednesday morning.

The company is a leader in high-pressure-based technologies, platforms and services to the life-sciences market worldwide since 2007.

The company continues to strengthen its balance sheet by converting a significant amount of debt into equity and with shrinking debt, it plans to uplist to a national exchange before the end of the year.

"Pressure BioSciences core Barocycler instrument and consumables business, based on our patented pressure cycling technology platform, also experienced solid quarterly growth. On a year-over-year comparison, quarterly sales of instruments, sample preparation accessories, and consumables increased 14%, 20%, and 22% respectively," said Damasio.

Pressure BioSciences develops pressure cycling technology (PCT) solutions and hundreds of labs utilize the company's pressure-based systems to extract proteins carefully from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

The company also holds two patents for Ultra Sheer Technology, which applies high-pressure levels greater than 20,000 pounds per square inch. The technology allows companies to extend the life of milk, and healthier drinks and juices, by reducing heat exposure in the preservation process through a combined application of elevated pressure and controlled times and temperatures.

READ: Pressure BioSciences developing breakthrough processing method for shelf-stable milk, dairy products

“We recently announced an agreement with Ohio State University to develop an innovative manufacturing technology for the extended preservation of high-quality milk and dairy products at room temperature without using chemical additives. This technology is based on our patented Ultra Shear Technology platform,” said CEO Richard T. Schumacher.

Pressure BioScience’s Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one of the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc last December.

"During the second quarter, we were delighted to announce the close of our first contract to evaluate our recently acquired PreEMT technology platform's ability to enhance the manufacturing process and to improve the quality of a biotherapeutic protein drug candidate,” said Schumacher.

The Harvard Medical School-trained serial entrepreneur said the company now had a “diverse patent estate” covering all three of its pressure-based platform technologies.

“In addition to continued increases in revenue from the sale of PCT-related products, we have now begun to generate solid revenue from our PreEMT platform. In addition, our UST platform will receive US$318,000 from an awarded USDA grant (thru Ohio State) to develop first-in-kind laboratory-bench and manufacturing-scale UST instruments,” said Schumacher.

“We believe these instruments, with their expected ability to make highly stable nanoemulsions, will forge multiple, potentially lucrative pathways into engagements in multiple industries, including food, pharmaceuticals, nutraceuticals, cosmetics, and more,” added Schumacher. “Consequently, we believe that the markets our patented, pressure-based technology platforms serve have now expanded to include many additional multi-billion-dollar areas, and that our recent developments have positioned us well to take advantage of these exciting and lucrative opportunities."

Operating loss for the second quarter decreased 24% to US$920,900 compared to US$1.2mln for the same period a year ago. However, loss per share was US$9.20 for the quarter compared to a loss of US$0.54 a year ago due to the conversion of debt and distribution of related dividends.

The move to pay down debt and bolster revenue puts the company’s finances on more solid ground, Schumacher said.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

 

]]>
Wed, 15 Aug 2018 10:52:00 -0400 https://www.proactiveinvestors.com/companies/news/202979/pressure-biosciences-posts-record-2q-product-and-services-revenue-lowers-operating-expenses-202979.html
<![CDATA[News - Pressure BioSciences expects to win additional patents for its Ultra Sheer Technology pressure-based platform ]]> https://www.proactiveinvestors.com/companies/news/202606/pressure-biosciences-expects-to-win-additional-patents-for-its-ultra-sheer-technology-pressure-based-platform-202606.html Richard Schumacher, CEO of Pressure BioSciences Inc (OTCQB:PBIO), expects to win additional patents in the coming months for the company’s pressure-based patented technology platform Ultra Sheer Technology, which gives milk and juice a longer shelf life, according to an interview on Uptick Newswire’s “Stock Day” podcast released Thursday.

The South Easton, Massachusetts, company already holds two patents for Ultra Sheer Technology, which applies high-pressure levels greater than 20,000 pounds per square inch. The technology allows companies to extend the life of milk, and healthier drinks and juices, by reducing heat exposure in the preservation process through a combined application of elevated pressure and controlled times and temperatures.

“So, if there are bacteria or viruses in the liquid food, the UST process will kill these pathogens, bringing their level down to what is known as manufacturing sterile,” Schumacher explained in the interview.

“This will allow the beverage to sit at room temperature storage for extended periods of time (weeks to months), without the need for refrigeration or chemical preservatives,” he added.

Big Picture: Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share

Last month, Pressure BioSciences announced that it will be collaborating with researchers at Ohio State University to work on this new method of making sure milk and juice are free of pathogens and chemical preservatives and will not require refrigerated transport. The goal of this working venture will be to bring Ultra Sheer Technology to market.

Read: Ohio State scientists to use Pressure BioSciences's Ultra Shear Technology to sterilize 'clean label' food and drinks

The collaborative project is funded by a US$891,000 grant from the US Department of Agriculture. Ohio State has granted Pressure BioSciences a US$318,000 sub-contract to build a working benchtop instrument and a pilot plant floor model Ultra Shear Technology machine.

Commencing commercial operations in 2007, Pressure BioSciences is a leader in high-pressure-based technologies, platforms and services to the life sciences market worldwide.

Shares in Pressure BioSciences rose nearly 2% to US$3.60 in Thursday's morning session.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

]]>
Thu, 09 Aug 2018 11:00:00 -0400 https://www.proactiveinvestors.com/companies/news/202606/pressure-biosciences-expects-to-win-additional-patents-for-its-ultra-sheer-technology-pressure-based-platform-202606.html
<![CDATA[News - Pressure BioSciences developing breakthrough processing method for shelf-stable milk, dairy products ]]> https://www.proactiveinvestors.com/companies/news/201166/pressure-biosciences-developing-breakthrough-processing-method-for-shelf-stable-milk-dairy-products-201166.html Pressure BioSciences (OTCMKTS:PBIO) announced Thursday that it is working with researchers at Ohio State University to develop and make available for commercialization a manufacturing technology that will play a role in the in the preservation of "clean label" foods and beverages.

The South Easton, Massachusetts company holds several patents for Ultra Shear Technology, which applies high-pressure levels greater than 20,000 pounds per square inch. The technology would allow companies to offer milk, and healthier drinks and juices by reducing heat exposure in the preservation process through a combined application of elevated pressure, intense shear forces and controlled times and temperatures. 

The collaborative project is funded by a US$891,000 grant from the US Department of Agriculture. Ohio State has granted Pressure BioSciences a US$318,000 sub-contract to build a working benchtop instrument and a pilot plant floor model Ultra Shear Technology machine.

READ: Ohio State scientists to use Pressure BioSciences's Ultra Shear Technology to sterilize 'clean label' food and drinks

Edmund Ting, senior vice president at Pressure BioSciences, will lead the development of the pilot-plant equipment that the researchers at the College of Food, Agricultural, and Environmental Sciences (CFAES) at Ohio State require.

"High Pressure Processing (HPP) has proven to be very effective in reducing food-borne pathogens and extending shelf-life in pre-packaged foods (e.g., juices and ready-to-eat meats), thus eliminating the need for chemical additives. However, HPP remains a batch process not capable of continuous flow, and because it is only a pasteurization process, and does not render food 'commercially sterile,' HPP-processed food must be shipped, stored, and maintained under refrigeration throughout the entire chain of distribution and retail sale,” said Ting, who is a co-inventor of Ultra Shear Technology.

“We believe that Ultra Shear Technology will provide economical solutions to these problems, and will offer an additional, clean label processing choice to both consumers and the food industry," he added.

According to GoCleanLabel.com, "clean label" foods contain "natural, familiar, simple ingredients that are easy to recognize, understand, and pronounce" with no artificial ingredients or synthetic chemicals. The "clean label" food market has been estimated at approximately US$62bn in the US and US$165bn worldwide.

"The ultimate goal of this collaborative project is for consumers to benefit from the increased availability of wholesome, healthy, better-tasting, shelf-stable, clean label liquid food and beverage options,” said Pressure BioSciences CEO Richard T. Schumacher.

“Imagine liquid foods like milk shipped and stored at room temperature for extended periods of time post-processing, while retaining superior nutritional and taste qualities. The advantages and cost-savings to the consumer and dairy industry could be game-changing. The advantages and cost savings to schools, the military, disaster relief agencies, and other such groups could be equally significant,” added the Harvard Medical School-trained serial entrepreneur.

Laying a strong financial foundation

Separately, the CEO said Pressure BioSciences had achieved “nine consecutive quarters” of increased product and services revenue on a year-over-year basis and 2018 was shaping up as a “banner year.”

The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

“We recently initiated the first project utilizing our recently acquired IP from the BaroFold acquisition, and that we believe this new CRO service could generate significant revenue in the near future," said Schumacher.

BIG PICTURE: Zacks upbeat on Pressure BioSciences' growth potential

Pressure BioScience’s Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

"With our core business showing consistent revenue growth, our BaroFold acquisition generating revenue much sooner than planned, and our Ultra Shear Technology platform getting off to an impressive start, we believe Pressure BioSciences has now positioned itself well for rapid, explosive growth in the months and years ahead."

Commencing commercial operations in 2007, Pressure BioSciences is a leader in high-pressure-based technologies, platforms and services to the life sciences market worldwide.

Contact Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive

]]>
Thu, 19 Jul 2018 10:36:00 -0400 https://www.proactiveinvestors.com/companies/news/201166/pressure-biosciences-developing-breakthrough-processing-method-for-shelf-stable-milk-dairy-products-201166.html
<![CDATA[News - Ohio State scientists to use Pressure BioSciences's Ultra Shear Technology to sterilize 'clean label' food and drinks ]]> https://www.proactiveinvestors.com/companies/news/200622/ohio-state-scientists-to-use-pressure-biosciences-s-ultra-shear-technology-to-sterilize-clean-label-food-and-drinks-200622.html Consumers who worry about the quality and contents of store-bought drinks can soon worry no more.

Researchers at the College of Food, Agricultural, and Environmental Sciences (CFAES) of Ohio State University are working on a remedy in conjunction with Pressure BioSciences' (OTCMKTS:PBIO) widely applicable Ultra Shear Technology.

The South Easton, Massachusetts, company holds several patents for Ultra Shear Technology, which applies high-pressure levels greater than 20,000 pounds per square inch. The technology would allow beverage makers to offer healthier drinks and juices by reducing heat exposure in the preservation process through a combined application of elevated pressure, intense shear forces and controlled times and temperatures.

VM Balasubramaniam, professor of food engineering at Ohio State, leads the research project, which is funded by a US$891,000 grant from the US Department of Agriculture. He said in a statement that the high-pressure-based Ultra Shear Technology can be used by food manufacturers in the healthier processing of beverages, sauces and condiments.

“Health-conscious consumers pay close attention to ingredients in beverages and tend to avoid products perceived to contain artificial or chemical-sounding ingredients, although such ingredients may be scientifically proven to be safe and functional,” said Balasubramaniam. “Development of cost-effective, next-generation, gentler industrial food manufacturing technologies for the preservation of healthy beverages is a critical need."

Pressure Bio's Ultra Shear Technology will play a significant role in the preservation of "clean label" foods and beverages. 

According to GoCleanLabel.com, "clean label" foods contain "natural, familiar, simple ingredients that are easy to recognize, understand, and pronounce" with no artificial ingredients or synthetic chemicals. The "clean label" food market has been estimated at approximately US$62bn in the US and US$165bn worldwide.

READ: 'We run Pressure BioSciences as if we were on Nasdaq or NYSE,' says CEO

Commencing commercial operations in 2007, Pressure BioSciences is a leader in high-pressure-based technologies, platforms and services to the life sciences market worldwide.

Edmund Ting, senior vice president at Pressure BioSciences, will lead the development of the laboratory-scale and pilot-plant equipment that the Ohio State researchers require.

“It has been rewarding to see the significant growth of high-pressure processing in many areas of food processing over the last 25 years,” said Ting, who is also a co-inventor of Ultra Shear Technology. “I believe Ultra Shear Technology has equal if not greater applications than high-pressure processing, both within and outside the food and beverage industries.”

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

 

]]>
Thu, 12 Jul 2018 13:36:00 -0400 https://www.proactiveinvestors.com/companies/news/200622/ohio-state-scientists-to-use-pressure-biosciences-s-ultra-shear-technology-to-sterilize-clean-label-food-and-drinks-200622.html
<![CDATA[Media files - Pressure BioSciences, The Ohio State University researchers team up to revolutionize food safety ]]> https://www.proactiveinvestors.com/companies/stocktube/9836/pressure-biosciences-the-ohio-state-university-researchers-team-up-to-revolutionize-food-safety-9836.html Thu, 12 Jul 2018 13:27:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/9836/pressure-biosciences-the-ohio-state-university-researchers-team-up-to-revolutionize-food-safety-9836.html <![CDATA[Media files - Pressure BioSciences has an eye toward uplisting as it strengthens balance sheet ]]> https://www.proactiveinvestors.com/companies/stocktube/9648/pressure-biosciences-has-an-eye-toward-uplisting-as-it-strengthens-balance-sheet-9648.html Thu, 21 Jun 2018 11:26:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/9648/pressure-biosciences-has-an-eye-toward-uplisting-as-it-strengthens-balance-sheet-9648.html <![CDATA[News - 'We run Pressure BioSciences as if we were on Nasdaq or NYSE,' says CEO ]]> https://www.proactiveinvestors.com/companies/news/199064/-we-run-pressure-biosciences-as-if-we-were-on-nasdaq-or-nyse-says-ceo-199064.html Richard T Schumacher, CEO of Pressure BioSciences Inc (OTCMKTS:PBIO) said Monday that the company continues to strengthen its balance sheet by converting a “significant amount” of debt into equity.

He said that with shrinking debt, the life-sciences company plans to uplist to a national exchange before the end of the year.

“Although we are a QB company on the OTC Marketplace, we run the company as if we were NASDAQ or NYSE-Amex listed. This is important, since we have expectations of moving up to a national stock exchange before the end of this year,” Schumacher told the “Stock Day Podcast” on the Uptick Network Radio.  

The Harvard Medical School-trained serial entrepreneur said Pressure BioSciences has been “working diligently” to meet the requirements necessary to uplist to a national exchange.

On June 12, the company converted an additional US$7.24mln of debt into equity, bringing the total amount of debt that it has converted into equity over the past four weeks to more than US$13.6mln.

As a result of its move to pay down its debt and the bolster its revenue, the company’s finances are on more solid ground. 

READ: Pressure BioSciences invigorates its balance sheet, converts additional US$7.24mln of debt into equity

Pressure BioSciences was founded in 1978 and is based in South Easton, Massachusetts. It develops pressure cycling technology (PCT) solutions and is a leader in high pressure-based technologies, platforms, and services.

Hundreds of labs utilize the company's pressure-based systems to extract proteins carefully from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

“We’re changing a paradigm that’s existed in labs for maybe 50 years,” said Schumacher.

Many other extraction methods used by over 500,000 researchers worldwide involve breaking cells open in more volatile ways that can actually damage the biomolecule contents or put researchers at risk.

PBI’s unique technology is more like squeezing a sponge, and the number of squeezes and level of pressure necessary for each unique cell type can be programmed into a computer that is part of their instrument. Individualizing profiles for human, plant, animal, and other normal or cancer cell types can promote consistency in research.

“High pressure has not really been utilized that much in the lab up to now, mainly because until we came along, there was really no way of safely getting high pressure into the lab,” Schumacher told the “Stock Day Podcast.” 

“We use pressures up to six times the pressure you would feel if you were standing at the bottom of Mariana’s Trench, with six miles of ocean on top of you. Now that is pressure,” he said.

Schumacher went on to tell the podcast that their pressure chambers can “safely reach levels up to 100,000 PSI, a staggering high” in the industry.

In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to more than 175 customers.

However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

Investment case

The Stock Day Podcast host Everett Jolly noted that with a market cap of about US$4.2mln and shares selling at just under US$3 it was a “great time for investors” to get a look at Pressure BioSciences.

“It’s an extremely undervalued company. It’s one of those undiscovered gems for which investors are always looking. The company has done very well over the past 18-24 months, and we expect they will continue to do well, yet their stock price is actually down about 75% over that time. At some point, we believe they will be discovered,” said Jolly.

“Until then, in our opinion, the stock price is not even close to a true reflection of the value of this company.”

Shares of the company were up 2.56% to US$4 in morning trading.

 

]]>
Mon, 18 Jun 2018 10:29:00 -0400 https://www.proactiveinvestors.com/companies/news/199064/-we-run-pressure-biosciences-as-if-we-were-on-nasdaq-or-nyse-says-ceo-199064.html
<![CDATA[News - Pressure BioSciences invigorates its balance sheet, converts additional US$7.24mln of debt into equity ]]> https://www.proactiveinvestors.com/companies/news/198715/pressure-biosciences-invigorates-its-balance-sheet-converts-additional-us724mln-of-debt-into-equity-198715.html Pressure BioSciences Inc (OTCMKTS:PBIO) continued to strengthen its balance sheet Tuesday with the conversion of an additional US$7.24mln of debt into equity, bringing the total amount of debt that has converted into equity over the past four weeks to more than US$13.6mln.

If the company successfully persuades more debt holders to follow suit and swap their debt for equity, it would increase the life sciences company’s chance of uplisting to a national exchange, such as Nasdaq, later this year.

“We are continuing to discuss the company's progress with remaining debt holders, and anticipate that several more may follow the lead of the approximate 40-plus investors who converted their debt into equity over the past 30 days,” said Pressure BioSciences CFO Joseph L. Damasio. "We believe such further conversions could reduce the amount of loan debt on our balance sheet by an additional 10% to 15%," he added.

READ: Callitas Health, ChemioCare and Pressure BioSciences make a splash at Proactive Investors forum

As a result of its move to pay down its debt and the bolster its revenue, the company’s finances are on more solid ground.  

“We are very pleased to have been able to clean up the balance sheet as much as we have over the past 30 days,” Pressure BioSciences CEO Richard Schumacher said in an emal to Proactive Investors. “Of course, there is more work to be done, which we are excited to be tackling.”

Schumacher noted that the company had successfully accessed debt for working capital. “This has allowed us to increase revenue, enlarge our customer base, enhance our instrument and consumables line, expand our sales and marketing reach, add much-needed manufacturing and development space, and strengthen other internal operational areas.”

He said that at a “strategic level,” debt capital had allowed the company to attain “initial progress and IP issuances” in its new Ultra Shear Technology platform, and to acquire all of BaroFold Corp.'s assets.

“We believe that both of these strategic programs will bring about substantial expansion in major new business segments,” said Schumacher.

The Harvard Medical School trained serial entrepreneur who has founded four companies is extremely enthusiastic about the first contract Pressure BioSciences has signed to sell its PreEMT platform and expects more deals to follow.

The Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition,” Schumacher had earlier told proactive investors. “It’s all coming together this year.”

WATCH: Pressure BioSciences CEO sees increased revenue on projects and services in 2018

In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to over 175 customers.

However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

Focus on uplisting to a national exchange

Meanwhile, Jeffrey N. Peterson, chairman of the board, said the conversion of “a majority of our loan debt into equity” would help Pressure BioSciences in its quest to uplist to a national exchange.

"We believe Pressure BioSciences Inc’s recent accomplishments, when combined with the conversion of a majority of our loan debt into equity, will materially facilitate progress towards our stated objective of uplisting to a national exchange (NASDAQ, NYSE/Amex) later in 2018,” said Peterson.

“We believe a national exchange trading platform will provide improved access to capital and trading volumes, and that these should result in a more attractive and higher-value recognition level for the company, benefitting all shareholders," he added.

Pressure BioSciences was founded in 1978 and is based in South Easton, Massachusetts. It develops pressure cycling technology (PCT) solutions and is a leader in the area of high pressure-based technologies, platforms, and services.

Hundreds of labs utilize the company's pressure-based systems to extract proteins from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

Pressure Biosciences' shares traded flat amid a broader market pullback.

]]>
Tue, 12 Jun 2018 10:29:00 -0400 https://www.proactiveinvestors.com/companies/news/198715/pressure-biosciences-invigorates-its-balance-sheet-converts-additional-us724mln-of-debt-into-equity-198715.html
<![CDATA[Media files - Pressure BioSciences CEO sees increased revenue on projects and services in 2018 ]]> https://www.proactiveinvestors.com/companies/stocktube/9331/pressure-biosciences-ceo-sees-increased-revenue-on-projects-and-services-in-2018 Fri, 18 May 2018 11:42:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/9331/pressure-biosciences-ceo-sees-increased-revenue-on-projects-and-services-in-2018 <![CDATA[News - Callitas Health, ChemioCare and Pressure BioSciences make a splash at Proactive Investors forum ]]> https://www.proactiveinvestors.com/companies/news/197230/callitas-health-chemiocare-and-pressure-biosciences-make-a-splash-at-proactive-investors-forum-197230.html Three companies blazing fresh tracks with unprecedented mechanisms and novel medicines made a splash at Proactive Investors’ Biotech and Life Sciences conference in New York on Wednesday.    

It's a great adrenaline-filled time to be in biotech, and the scientific entrepreneurs spearheading Callitas Health Inc. (CNSX:LILY), ChemioCare USA Inc and  Pressure BioSciences Inc (OTCMKTS:PBIO) shared their stories in an event held Wednesday evening at the 3 West Club in New York City.

The presentations by the three CEOs was met with enthusiasm by a full house of institutional and retail investors, high net-worth individuals, fund managers and analysts.

Investors perked up as the companies talked about clinical trial results and potential orphan drugs that offer rare opportunities to make money.

“Biotechs are still popular with investors for all the right reasons: there’s a lot of M&A activity, solid clinical data, regulatory reviews, upcoming scientific conferences and orphan drugs,” said Sheldon S. Traube at Kareg Research, who attended the event. “They offer so much opportunity.”

Patching the problem of chemo-induced nausea

The biopharma sector is discovering and developing new transformative therapies for patients across a huge range of diseases.

In March, industry veteran Pedro Lichtinger and Dr. Fotios Plakogiannis, who operates a lab in Long Island City, bootstrapped a biotech start-up called ChemioCare USA Inc. It’s working on novel skin patch technology for treating chemo-induced nausea and vomiting.

It leverages transdermal technology using adhesive patches to deliver medicines through the skin. ChemioCare’s product pipeline includes four different single active ingredient patches using proprietary formulations. Its chemio-ondan patch which delivers a sustained dose over three to five days is furthest along the development process.

The company is also working on a combination patch involving a mixture of two or three agents dosed over to two-to-five days.

“The revenue potential of each patch is between US$400mln and US$1bn,” pointed out ChemioCare CEO Pedro Lichtinger, who has an MBA from Wharton and an engineering degree from the National University of Mexico.

“Compared to new molecular entity drug development, ChemioCare is low risk, fast to market with limited capital needs. We are reformulating well known generic drugs with the objective of achieving on label meaningful improvements,” he added.

The CEO said the biotech’s development programs “are designed to follow the 505(b)2 pathway” and require a relatively low financial investment.

In plain terms, a company using the 505(b)(2) FDA drug approval pathway relies on clinical data or literature produced by other companies.

Eyes set on IPO in 10 months

Lichtinger, who has an impressive 37-year career in biotechnology, is taking the up-and-coming biotech public by March 2019.

“In 10 months, we will be in a position to launch an IPO. We are going to do a dual listing in Nasdaq and Canada,” said Lichtinger who has a proven track record of building commercial and R&D capabilities at aspiring companies that need cash to develop.

WATCH: ChemioCare plans IPO and raise funds to bring 'transformative' drug to the market

No stranger to taking companies public, Lichtinger was formerly the CEO of Asterias Biotherapeutics Inc. (NYSEAMERICAN:AST) and Optimer Pharmaceuticals Inc (NASDAQ:OPTR). He also has a 16-year stint with Pfizer Inc. under his belt.

“I think there will be terrific demand for ChemioCare’s patches because the existing regimens have a lot of side effects. There’s significant unmet medical need,” said Irma Calara Nielson, a savvy investor looking for ground-floor investments.

Callitas Health focuses on innovation

Callitas Health, a clinical-stage company focused on weight management and female health, has big plans for a broad product portfolio. It is developing innovative remedies for weight management, female sexual health, cannabis delivery technologies and other proprietary drugs.

In February, it hired Freyeur & Trogue (F&T) to provide development consulting to help optimize its large product portfolio development and commercialization.

“We have two blue sky assets which have massive revenue potential,” said Interim Callitas Health CEO James Thompson.

Notably, late last year, Callitas received a successful response from the US FDA on its pre-investigational new drug (IND) application for its Extrinsa topical gel to treat female sexual dysfunction (FSD).

Sitting pretty on a large market

Thompson said that Extrinsa could be a US$1bn opportunity. Addyi, the only drug currently approved for the treatment of female sexual desire disorder was purchased by Valeant Pharmaceuticals International Inc (NYSE:VRX) from Sprout for more than US$1bn in 2016.

Valeant had estimated that sales would ramp up to US$1bn annually for this drug, and it makes no claims to treat orgasm disorders, so the potential market for Extrinsa should be higher.

The company is also working on C – 103, the reformulated weight loss treatment, which was Orlistat (which had unwelcome side effects). The firm has targeted US$500mln in revenue from C-103 from the US market alone as first-year revenues, once it is approved by the FDA.

“We have patent-pending pharmaceutical status from the US patent office concerning the orally dissolvable delivery technology concerning cannabinoids branded as CannaMint Strips by Callitas,” said Thompson.

The firm is planning to license the technology to manufacturers and distributors in North America.

The company recently signed partnership agreements with two undisclosed Californian companies, which permits Calitas to market and sell its CannaMint strips for both tetrahydrocannabinol (thc) and cannabidiol (cbd).

2018 is the year for Pressure BioSciences

Serial entrepreneur Richard Schumacher, who is the CEO of Pressure BioSciences Inc (OTCMKTS:PBIO), expects 2018 to be a “banner year” for the firm.

In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to over 175 customers.

However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

“We have expanded our sales force from one to five and this will boost our 2018 revenue,” said Schumacher.

Hundreds of labs utilize the company's pressure-based systems to extract proteins from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

The Harvard Medical School trained serial entrepreneur who has founded four companies is extremely enthusiastic about the first contract Pressure BioSciences has signed to sell its PreEMT platform and expects more deals to follow.

The Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition,” said Schumacher. “It’s all coming together this year.”

A sixth sense for biotech can make investors a lot of money as the margins are high and the opportunities are very big.   

“All three companies had exciting technologies in emerging growth areas and they are all looking to take new technologies to market or improving existing technologies,” said Kevin McGarth of strategic advisory firm TraDigital IR, who attended the event.

 

]]>
Thu, 17 May 2018 16:34:00 -0400 https://www.proactiveinvestors.com/companies/news/197230/callitas-health-chemiocare-and-pressure-biosciences-make-a-splash-at-proactive-investors-forum-197230.html
<![CDATA[News - Pressure BioSciences shares soar on shrinking debt and jump in first-quarter revenue ]]> https://www.proactiveinvestors.com/companies/news/197036/pressure-biosciences-shares-soar-on-shrinking-debt-and-jump-in-first-quarter-revenue-197036.html Investors sent shares of Pressure BioSciences Inc (OTCMKTS:PBIO) soaring Tuesday after the life science group reported both a jump in first-quarter revenue thanks to an uptick in instrument sales, and said it has shrunk its debt.

By the afternoon, Pressure Bio's shares were up about 19% to US$3.90.

The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks partly to booming sales of the company’s laboratory instruments which utilize pressure to control bio-molecular interactions.

Sales of instruments jumped 8% to $420,089 in the first quarter compared with $396,095 last year while sales of related consumables rose 18% to $74,698 compared with $63,264 for the same period in 2017.

Pressure BioSciences also successfully converted US$6.39mln worth of debentures held by 22 debt holders into series AA preferred stock, which means that it paid off 92% of its 2015/2016 outstanding debenture debt on its balance sheet as of the end of last March.

If the company successfully persuades more debt holders to follow suit and swap their debt for equity, CEO Richard Schumacher says it would increase the company’s chance of uplisting to a national exchange such as the Nasdaq later this year.“We are in discussions with other note-holders about the possible conversion of debt into equity in the near future,” said Schumacher in a statement. “If some of these additional loans are also converted into equity, the projected balance sheet on June 30, 2018, will be materially stronger than the balance sheet as of March 31, 2018."

READ: Pressure Biosciences chief bullish on sale of new PreEMT platform

As a result of its move to pay down its debt and the bolstering of its revenue, the company’s loss shrank 24% to US$1.64 in the first quarter, down from a loss of US$2.16 in the year-ago quarter.

Among wins in the quarter is the signing of the first contract to evaluate the ability of the company’s patented PreEMT platform to improve the manufacturing process for protein therapeutic drug candidates.

Pressure BioSciences also entered a two-year global co-marketing and distribution agreement with ISS Inc, a supplier of high-pressure optical cell systems used for laboratory analysis. Working together, the two companies plan to replace ISS’s manual pressure generator with Pressure BioSciences’ computer-controlled, automated instruments.

]]>
Tue, 15 May 2018 13:31:00 -0400 https://www.proactiveinvestors.com/companies/news/197036/pressure-biosciences-shares-soar-on-shrinking-debt-and-jump-in-first-quarter-revenue-197036.html
<![CDATA[News - Pressure Biosciences chief bullish on sale of new PreEMT platform ]]> https://www.proactiveinvestors.com/companies/news/196748/pressure-biosciences-chief-bullish-on-sale-of-new-preemt-platform-196748.html Richard Schumacher, president and chief executive of Pressure BioSciences Inc. (OTCQB:PBIO), is extremely enthusiastic about the first contract the group has signed to sell its PreEMT platform and expects more deals to follow.

The Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition,” Schumacher noted in an interview held as part of the “Stock Day” podcast. “We view this as both significant and exciting and believe that additional contracts will soon be secured.”

In addition to the recent contract reached with the biopharma company, two other protein-based biotherapeutic companies have approached Pressure Biosciences in the last several weeks to ask about potential collaborations with similar studies.

READ: Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018

PreEMT technology improves the quality of manufacturing biopharma products and decreases manufacturing costs by as much as US$2mln to US$10mln per year for each commercial biologic drug.

Hundreds of labs already utilize Pressure Bioscience's pressure-based systems – which take advantage of pressure cycling technology – to extract proteins from all types of cells, whether it be plant, animal or human and whether the cells are normal or cancerous.

Pressure Biosciences has developed three new lab instruments that will be released within the next year and Schumacher is bullish about the company’s outlook for the year. “We are very excited about the potential of 2018 – we see this year shaping up well,” he said on the “Stock Day” podcast.

Pressure Biosciences shares closed up 5.7% to US$3.70 on Wednesday.

]]>
Thu, 10 May 2018 08:30:00 -0400 https://www.proactiveinvestors.com/companies/news/196748/pressure-biosciences-chief-bullish-on-sale-of-new-preemt-platform-196748.html
<![CDATA[News - Pressure BioSciences reaches a deal to contract out its PreEMT platform ]]> https://www.proactiveinvestors.com/companies/news/196371/pressure-biosciences-reaches-a-deal-to-contract-out-its-preemt-platform-196371.html Pressure BioSciences Inc (OTCMKTS:PBIO), a life-science group that makes instruments which utilize pressure to control bio-molecular interactions, has signed a deal with an unnamed international biopharmaceutical company, which will assess the potential of its PreEMT platform.

The hope is that the PreEMT platform – which uses high pressure to help drug companies develop protein-based therapeutics - can be used to manufacture and improve the quality of a key protein-based drug, which is currently under development at the undisclosed biopharmaceutical group.

The manufacture of therapeutic proteins is difficult and complex and producing a typical protein drug may include more than 5,000 steps. As a result, even in the best laboratories, it is typical for protein therapeutics to fail in manufacturing.   

“We believe this unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality novel protein therapeutics and lower the cost of existing formulations," said Dr. Alexander Lazarev, vice president of research & development. “PreEMT can be applied to many therapeutic proteins. … It is scaleable and practical for standard manufacturing processes.”

READ: Pressure BioSciences CEO says company poised for 'solid year' in 2018

Richard Schumacher, Pressure BioScience’s president and chief executive, said the contract with the international biopharma group will be wrapped up in three to four months.  He noted that several other biopharmaceutical companies are interested in evaluating the group’s PreEMT platform and said that if deals are done, Pressure BioScience will receive royalty revenues.

“Should the PreEMT technology result in more efficient production of high quality protein-based therapeutics for any biopharmaceutical company developing new protein-based therapeutics, manufacturing-scale licenses have the potential to generate millions of dollars in annual royalty revenue,” Schumacher said.

There are over 200 therapeutic proteins and peptides now approved for clinical use in the U.S. These drugs have changed therapy options for cancer and blood disorders and are also a treatment option for autoimmune diseases.

Pressure BioScience’s shares were flat at US$3.75 in early afternoon trade.

]]>
Thu, 03 May 2018 12:02:00 -0400 https://www.proactiveinvestors.com/companies/news/196371/pressure-biosciences-reaches-a-deal-to-contract-out-its-preemt-platform-196371.html
<![CDATA[News - Pressure BioSciences CEO says company poised for 'solid year' in 2018 ]]> https://www.proactiveinvestors.com/companies/news/194662/pressure-biosciences-ceo-says-company-poised-for-solid-year-in-2018-194662.html Pressure BioSciences Inc. (OTCQB:PBIO) Chief Executive Officer Richard T. Schumacher said he expects 2018 to be “another solid year” for the Massachusetts-based company, helped in part by the acquisition of BaroFold intellectual property.

“The results we achieved in 2017 were especially rewarding in that they were achieved with only one dedicated salesperson,” Schumacher said recently on Uptick Newswire’s “Stock Day” podcast. “The enhancements we are implementing in our products, our sales and marketing capabilities, and our corporate infrastructure will allow us to better design, create, sell, support and distribute our product line in 2018.”

READ: Pressure BioSciences reports 20% bump in 4Q sales, expects continued growth in its main business

The life-science group that makes laboratory devices said last week that fourth-quarter sales gained 20% as its product and services business continues to grow. Pressure BioSciences's sales of instruments rose 55% to US$317,498 in the quarter and 21% to US$1.46mln for the full year. Revenue for consumables gained 20% to US$60,108 in the quarter, while it climbed 30% to US$260,331 for the year.

The CEO also cited new patents in Pressure BioSciences’s Ultra Shear Technology platform and the release of its GMP-compliant software as areas that will contribute to results this year.

“We believe these new assets will help expand our customer base, take us further down the path to profitability and help increase shareholder value,” Schumacher said.

]]>
Tue, 10 Apr 2018 11:56:00 -0400 https://www.proactiveinvestors.com/companies/news/194662/pressure-biosciences-ceo-says-company-poised-for-solid-year-in-2018-194662.html
<![CDATA[News - Pressure BioSciences reports 20% bump in 4Q sales, expects continued growth in its main business ]]> https://www.proactiveinvestors.com/companies/news/194189/pressure-biosciences-reports-20-bump-in-4q-sales-expects-continued-growth-in-its-main-business-194189.html Pressure BioSciences Inc. (OTCMKTS:PBIO), a life-science group that makes laboratory devices, saw a 20% bump in sales for the fourth quarter as its product and services business continues to grow.

Revenue in the period grew to US$502,708, helped by the product and services unit, which expanded by 25%. Revenue for 2017 climbed as well, to US$2.2mln from US$1.9mln a year earlier.

Chief Executive Officer Richard Schumacher said in March that the firm is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc.

READ: Pressure BioSciences chief presents rosy view of growth prospects in podast interview

Pressure BioSciences, which makes instruments that utilize pressure to control bio-molecular interactions, said in a statement Tuesday that accompanied its fourth-quarter earnings that it expects “continued double-digit” growth rates in its product and services business.

“We believe the accomplishments of the past several years have set the stage for future success,” Schumacher said. “We remain very, very excited about 2018.”

While operating loss widened in the fourth quarter, it was on higher expenses linked to expanding the company’s sales team, the Massachusetts-based firm said in a statement. The loss per common share was US$2.37 vs. income of US$3.13 a share in the year-earlier period.

Pressure BioSciences's sales of instruments rose 55% to US$317,498 in the quarter and 21% to US$1.46mln for the full year. Revenue for consumables gained 20% to US$60,108 in the quarter, while it climbed 30% to US$260,331 for the year.

The shares added 1.3% to US$3.80 as of 1:10 p.m. on Thursday.

]]>
Thu, 05 Apr 2018 13:12:00 -0400 https://www.proactiveinvestors.com/companies/news/194189/pressure-biosciences-reports-20-bump-in-4q-sales-expects-continued-growth-in-its-main-business-194189.html
<![CDATA[News - Pressure BioSciences chief presents rosy view of growth prospects in podast interview ]]> https://www.proactiveinvestors.com/companies/news/193096/pressure-biosciences-chief-presents-rosy-view-of-growth-prospects-in-podast-interview-193096.html Richard Schumacher, chief executive of Pressure BioSciences Inc (OTCMKTS:PBIO), a Massachusetts-based life science group which makes laboratory devices, is on the road, touting the expansion of the firm’s business.

The chief of this maker of instruments which utilise pressure to control bio-molecular interactions said his company is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc., an Illinois-based designer of scientific instruments.

Schumacher said on Tuesday in an interview with Uptick Newswires "Stock Day" podcast: “We believe we have set the table to facilitate even greater revenues with the deployment of an experienced, trained, and dedicated field sales team, the acquisition of the BaroFold, Inc. assets – including 8 important patents that integrate well with our own seventeen patents, and our very recently announced co-marketing and distribution relationship with ISS Inc.”

Pressure BioSciences reached the two-year agreement with ISS last month.

One of the products ISS makes is a spectrophotometer -- an instrument used in drug discovery and development -- the pressure for which is usually generated by an “archaic” hand-cranking mechanism.

As its name suggests, Pressure Bio, meanwhile, manufactures automated pressure generators for laboratories which can increase and decrease pressure “like a light switch.”

PBIO’s Hub 440 and the more powerful Hub 880 sell for between US$30,000 and US$50,000 each.

The company doesn’t sell many of these units at the moment, Schumacher said last month, but both parties are expecting to sell more of their respective systems on the back of the tie-up.

In midday trading, shares of the company were flat at US$4.80.

]]>
Tue, 13 Mar 2018 09:55:00 -0400 https://www.proactiveinvestors.com/companies/news/193096/pressure-biosciences-chief-presents-rosy-view-of-growth-prospects-in-podast-interview-193096.html
<![CDATA[News - Pressure BioSciences expecting sales boost from new co-marketing deal with ISS ]]> https://www.proactiveinvestors.com/companies/news/191662/pressure-biosciences-expecting-sales-boost-from-new-co-marketing-deal-with-iss-191662.html Pressure BioSciences Inc (OTCQB:PBIO) has signed a two-year worldwide co-marketing and distribution agreement with Illinois-based medical instruments maker ISS.

One of the products ISS makes is a spectrophotometer - an instrument used in drug discovery and development - the pressure for which is usually generated by an “archaic” hand-cranking mechanism.

As it name suggests, Pressure Bio manufactures automated pressure generators which can increase and decrease pressure “like a light switch”.

‘If you buy this, you should buy this too’

The two companies have been in talks for a little while about bringing their two systems together and after Wednesday's tie-up they will actively look to market each other’s devices.

“We are going to sell our equipment...to customers that reach out to us and we will then let [the customers] know that they can talk directly to [ISS] about buying the spectrophotometer from them,” said PBIO President and chief executive Richard Schumacher in a conference call.

“If [ISS] gets requests coming in they will either shuttle them to us or sell the pressure cell and the spectrophotometer and then send [the customer details] to us to sell the pressure generating equipment.”

Pressure’s VP marketing and sales, Nate Lawrence, added: “The unique combination of PBI’s high pressure generators and ISS’s high pressure optical cell system is expected to greatly benefit scientists in academic institutions, industry and governments who study biological samples and processes at the molecular level.”

Tie-up should increase sales

PBIO’s Hub 440 and the more powerful Hub 880 sell for between US$30,000-US$50,000 each.

The company don’t sell many of these units at the moment, Schumacher said, but both parties are expecting to sell more of their respective systems on the back of the tie-up.

Pressure Bio and ISS will both be at the Biophysical Society in San Francisco this weekend, where both parties will talk about their new partnership.

Shares were flat at US$3.85 on Wednesday.

]]>
Wed, 14 Feb 2018 11:20:00 -0500 https://www.proactiveinvestors.com/companies/news/191662/pressure-biosciences-expecting-sales-boost-from-new-co-marketing-deal-with-iss-191662.html
<![CDATA[News - Pressure BioSciences expecting banner year for the company in 2018 ]]> https://www.proactiveinvestors.com/companies/news/190776/pressure-biosciences-expecting-banner-year-for-the-company-in-2018-190776.html Pressure BioSciences Inc's (OTCMKTS:PBIO) boss Richard Schumacher expects 2018 to be a “banner year” for the firm.

In a 'Stock Day' podcast Schumacher ran through a number of aspects of recent progress, including that it had sold more PCT (pressure cycling technology) machines in the third quarter of 2017 than it had ever sold in a single quarter before.

Revenues for the firm's products and services increased 21% in that quarter alone, with consumable products increasing 158% - the largest increase in consumables the firm ever reported.

Schumacher also said a big multinational company, who was a customer, had also been working with Pressure to produce a software upgrade for its flagship Barocycler 2320EXTREME instrument.

Pressure believes this new instrument will now be "highly desirable" in its niche life sciences and pharmaceutical markets.

Also discussed was the newly established Center of Excellence in China, which will showcase three of the company's PCT instruments and many related consumable products.

"Being the first Center of Excellence in Asia, the company will focus on the Chinese biopharmaceutical and biological research markets where there is a large community of bioscience engineers and scientists and centers for biotechnology advancements," said Schumacher.

The firm's acquisition of BaroFold Inc had increased the IP (intellectual property) estate of the company by eight issued and several pending patents, and had allowed the company to offer a number of important new applications to its worldwide base of nearly 200 customers with PBIO instrumentation, he added.

Watch the Podcast HERE...

]]>
Mon, 29 Jan 2018 13:07:00 -0500 https://www.proactiveinvestors.com/companies/news/190776/pressure-biosciences-expecting-banner-year-for-the-company-in-2018-190776.html
<![CDATA[News - Pressure BioSciences says software upgrade enhances Barocycler 2320EXT instrument ]]> https://www.proactiveinvestors.com/companies/news/189111/pressure-biosciences-says-software-upgrade-enhances-barocycler-2320ext-instrument-189111.html Pressure BioSciences Inc (OTCMKTS:PBIO) says its redesigned software for its pressure-based Barocycler 2320EXTREME instrument will "significantly" expand its uses and appeal in the biopharma market.

The enhancement makes the 2320EXT device one of the few good manufacturing practices (GMP) compliant sample preparation systems available in the worldwide life sciences market today, the company said.

READ - Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018

The machine is mainly used to prepare samples (tissues, cells, proteins) for analysis and has been installed in research and manufacturing laboratories worldwide.

"GMP compliance is not only mandated by the U.S. Food and Drug Administration and equivalent regulatory bodies worldwide, it is also widely accepted by the world's biopharmaceutical companies as the best - if not the only - way to bring a new product to market," noted Dr Alexander Lazarev, the vice president of R&D (research and development) at  Pressure BioSciences.

GMP covers all aspects of production, from starting materials to the final released product.

Having GMP-compliant features should allow the Barocycler 2320EXT to be used in multiple departments within the same company, and for multiple applications, said the US-listed firm.

Sample preparation is often complex, time-consuming, and one of the most error-prone steps in research.

READ - Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share

It is also a large and growing market, estimated currently at US$6 billion worldwide.

It's been a busy month for Pressure BioSciences.

It has announced the acquisition of all assets of BaroFold Inc, which is expected to enhance revenues and increase its IP (intellectual property) portfolio.

BaroFold, among other assets, has developed PreEMT technology, which improves the quality of manufacturing  biopharma products and decreases manufacturing costs (by as much as US$2-10mln per year per commercial biologic drug), the firm said.

]]>
Wed, 20 Dec 2017 11:51:00 -0500 https://www.proactiveinvestors.com/companies/news/189111/pressure-biosciences-says-software-upgrade-enhances-barocycler-2320ext-instrument-189111.html
<![CDATA[News - Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018 ]]> https://www.proactiveinvestors.com/companies/news/188823/pressure-biosciences-expects-barofold-inc-to-have-significant-impact-on-revenues-in-2018-188823.html Pressure BioSciences Inc (OTCMKTS:PBIO) says its acquisition of all assets of BaroFold Inc is expected to enhance revenues and will increase its IP (intellectual property) portfolio.

BaroFold, among other assets, has developed PreEMT technology, which improves the quality of manufacturing  biopharma products and decreases manufacturing costs (by as much as US$2-10mln per year per commercial biologic drug), the firm said.

Pressure BioSciences has developed unique and superior pressure cycling technology (PCT) to prepare biological lab samples.

"This acquisition will significantly increase PBI's IP estate in high-pressure technologies with the addition of eight issued and several pending patents," said Alexander Lazarev, vice-president of R&D for PBI.

"These patents give us freedom to operate in several important areas for biologics research and manufacturing: protein folding, re-folding and disaggregation.

"They also provide us the right to grant licenses to third parties to practice the PreEMT and other technologies in both research laboratories and in biopharmaceutical manufacturing, the latter being a very large and rapidly growing field."

Dr Nathan Lawrence, of Pressure BioSciences, added: "Importantly, our existing high-pressure equipment is well-suited to the performance of the R&D and process development studies needed for the development of these biopharmaceutical manufacturing applications and markets.

"In fact, it will quickly become evident that our new, award-winning Barocycler 2320EXT high-pressure instrument was designed with technologies like PreEMT bench scale R&D in mind.

"With our worldwide customer base, supported by our expanded sales and marketing capabilities and our growing equipment and consumables product lines, we believe the newly-acquired BaroFold IP will have a significant impact on our revenues in 2018 and beyond."

Pressure BioSciences shares are down 4.50% to US$3.82 in New York.

]]>
Thu, 14 Dec 2017 12:22:00 -0500 https://www.proactiveinvestors.com/companies/news/188823/pressure-biosciences-expects-barofold-inc-to-have-significant-impact-on-revenues-in-2018-188823.html
<![CDATA[News - Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share ]]> https://www.proactiveinvestors.com/companies/news/187932/zacks-upbeat-on-pressure-biosciences-growth-potential-targets-us10-a-share-187932.html Pressure BioSciences Inc (OTC:PBIO) has received an upbeat write-up from Zacks smallcap research, which it reckons is more like a development stage biotech and targets US$10 each for the shares (current price: US$4.20).

The group operates in the "rather large, but underserved" research services market, says Zacks.

It has developed a "unique and superior pressure" cycling technology (PCT) to prepare biological laboratory samples.

The research group said sales had not been stellar so far, but this was "understandable".

PCT quite a new technology

"Pressure cycling technology is quite new to most customers in the sample preparation market, and the costs for PCT are also higher than those for most existing technologies. Therefore, rollout of the PCT platform will take time."

Earlier this month,  Pressure said it was moving firmly towards profitability as it unveiled record revenues for the third quarter.

It reckons this revenues growth will not only continue in the fourth quarter and beyond, but accelerate to a greater rate as new sales team begins to meet with existing and potential customers throughout the US.

Total revenue in the third quarter was up 21% to US$646,061 from US$535,334 in the same period last year, which was a new record for any quarter.

Products  and services revenue increased 21%  to US$603,726, a new quarterly record, while consumable sales increased 158% to US$84,594, again a new quarterly record.

Grant revenue increased 23% to US$42,335 in the quarter, versus 34,385 in the third quarter last year.

So far, and significantly, fourth quarter purchase orders and purchase indications (90% estimated probability of closing) through to early November have already exceeded products and services revenue for the full 2016 fourth quarter, Pressure also noted.

Poised to boost top and bottom line..?

In its note, Zacks said: "With a rapidly growing market worldwide, combined with its unique technology and broad range of product offering, the company is well positioned to boost its top line and bottom line in the coming years.

"According to our long term financial model, the company's products and services revenue will grow at a compound annual growth rate (CAGR) of 79% in the next four fiscal years from 2017 to 2020."

Pressure Biosciences will become profitable in fiscal 2019 with an EPS of $0.01, it adds.

Achieving the CE marking for the Barocycler 2320EXT in February was an important next step in the company' s commercialization plans for this powerful and enabling sample preparation instrument, highlights Zacks.

"The company recently signed agreements with several strong distribution partners in Europe, the SCIEX co-marketing agreement is entering its second year (SCIEX is a global provider of laboratory instrumentation to the life sciences area, with a large presence in Europe."

And now with a significantly expanded sales capabilities, as well as the newly established multinational co-marketing partner SCIEX, Zacks reckons revenue will grow significantly in the fourth quarter and beyond.

Our price target values the company at $11 million in market cap.

Valuation conservative..

"This valuation is still very conservative in our view. As long as the company can execute on its growth strategy correctly, we believe this goal is achievable. Patient investors will get rewarded."

Shares eased 1.18% to US$4.20 on Tuesday.

]]>
Tue, 28 Nov 2017 15:36:00 -0500 https://www.proactiveinvestors.com/companies/news/187932/zacks-upbeat-on-pressure-biosciences-growth-potential-targets-us10-a-share-187932.html
<![CDATA[News - Pressure BioSciences moves towards profitability as it reveals strong revenue growth in latest quarter ]]> https://www.proactiveinvestors.com/companies/news/187254/pressure-biosciences-moves-towards-profitability-as-it-reveals-strong-revenue-growth-in-latest-quarter-187254.html Pressure BioSciences Inc (OTCMKTS:PBIO) says it's moving firmly towards profitability as it unveiled record revenues for the third quarter.

The pressure cycling specialist said it reckons this growth in revenues will not only continue in the fourth quarter and beyond, but accelerate to a greater rate as new sales team begins to meet with existing and potential customers throughout the US.

" We have spent a lot of time and money over the past few years preparing for this opportunity. We believe we are ready and taking all necessary actions to grow our momentum and fully exploit the exciting growth and new markets potential that we have long envisioned," Richard T. Schumacher, president and chief executive, said.

The life sciences group develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn sample preparation market.

Total revenue in the third quarter was up 21% to US$646,061 from US$535,334 in the same period last year, which was a new record for any quarter.

Products  and services revenue increased 21%  to US$603,726, a new quarterly record, while consumable sales increased 158% to US$84,594, again a new quarterly record.

Grant revenue increased 23% to US$42,335 in the quarter, versus 34,385 in the third quarter last year.

So far, and significantly, fourth quarter purchase orders and purchase indications (90% estimated probability of closing) through to early November have already exceeded products and services revenue for the full 2016 fourth quarter, Pressure noted.

Operational highlights of the quarter just gone included the receipt of the first two issued patents on the high pressure-based Ultra Shear Technology (UST).

The firm also established its first Center of Excellence in Asia, expected to significantly impact PBI's expansion into China.

]]>
Tue, 14 Nov 2017 12:37:00 -0500 https://www.proactiveinvestors.com/companies/news/187254/pressure-biosciences-moves-towards-profitability-as-it-reveals-strong-revenue-growth-in-latest-quarter-187254.html
<![CDATA[News - Pressure BioSciences bidding to expand into large Chinese life sciences market ]]> https://www.proactiveinvestors.com/companies/news/186676/pressure-biosciences-bidding-to-expand-into-large-chinese-life-sciences-market-186676.html Pressure BioSciences Inc (OTCMKTS:PBIO) is bidding to take its sample preparation technology into the large life sciences market in China.

It comes as professor Tiannan Guo's laboratory at Westlake Institute for Advanced Study (WIAS) has been named as Pressure's first Center of Excellence (CoE) in China.

Guo and  Professor Ruedi Aebersold in Switzerland are co-developing PCT-SWATH, which is a novel method, which combines Pressure BioSciences' patented pressure cycling technology (PCT) platform with cutting-edge analytical capabilities of SCIEX's mass spectrometry SWATH method.

SCIEX, the life sciences tech firm, signed an exclusive co-marketing agreement with the firm in early 2016 to improve protein quantitation in complex samples.

"We are very pleased that Professor Guo will be leading the effort to establish and then direct our first CoE in China, " said Dr Nate Lawrence, vice president of marketing and sales.

"This Center is the first of its kind in Asia and joins our other Centers of Excellence in Europe and Australia as an important pillar in our global marketing and sales strategy.

"We believe Professor Guo's vast experience with the PCT platform, his expertise in proteomics and lipidomics, and his fluency in both Chinese and English will be invaluable in helping PBI quickly and successfully expand into the large life sciences market in China."

Guo added: "I believe strongly that PCT will have a significant impact in helping research scientists in China and around the world make new discoveries in multiple fields, including proteomics, genomics, lipidomics, and metabolomics."

Pressure BioSciences Inc shares were unchanged at US$3.94 at the time of writing.

]]>
Thu, 02 Nov 2017 10:28:00 -0400 https://www.proactiveinvestors.com/companies/news/186676/pressure-biosciences-bidding-to-expand-into-large-chinese-life-sciences-market-186676.html
<![CDATA[News - Pressure BioSciences' Schumacher upbeat on market potential for its life science tools ]]> https://www.proactiveinvestors.com/companies/news/186218/pressure-biosciences-schumacher-upbeat-on-market-potential-for-its-life-science-tools-186218.html Pressure BioSciences Inc (OTCMKTS:PBIO) chief Richard T. Schumacher told a recent interview in New York that he believes the market opportunity for the group's tools, which prepare samples, runs into multi billions of US dollars.

"We think there's at least 500,000 researchers and at least 80,000 labs that can use of our system," he told the SNNLive video interview.

WATCH IT HERE...

"Right now we are in about 165 labs of the 80,000. We are a small company. We've had one salesperson for the last nine years. We've had minimal money to develop things. We had one instrument that was run by a microprocessor. Things have really changed for us in the last year."

Schumacher explained how the group now had six salespeople, with four new instruments that are ready to come out on top of the one it already had.

"We now have a brand new instrument that is computer driven, not run by a microprocessor, has tremendous software."

Earlier this month, Pressure BioSciences said it was very excited about the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.

The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.

Last week, Pressure said it was to collaborate with Phasex Corporation to combine its ultra shear technology with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

Pressure Biosciences's Schumacher has also conducted an interview with NetworkNewsWire (NNW), a financial news and publishing company.

WATCH IT HERE.

"We supply instruments and consumables to life science laboratories all over the world," says Schumacher.

"These are the laboratories that are aggressively looking for the next billion-dollar drug, the next cure, the next preventive strategy, the next vaccine."

]]>
Wed, 25 Oct 2017 16:22:00 -0400 https://www.proactiveinvestors.com/companies/news/186218/pressure-biosciences-schumacher-upbeat-on-market-potential-for-its-life-science-tools-186218.html
<![CDATA[News - Pressure BioSciences hires NetworkNewsWire for corporate communications ]]> https://www.proactiveinvestors.com/companies/news/186038/pressure-biosciences-hires-networknewswire-for-corporate-communications-186038.html Pressure BioSciences Inc (OTCQB: PBIO), the technology and sample market specialist, revealed it had hired corporate communications firm NetworkNewsWire (NNW).

"Our award-winning proprietary technology is being installed in some of the top research laboratories around the world, we have just gone from one to six sales personnel, we will finish the development and release four new instruments to the market over the next 18 months, and our revenue continues to grow year-over-year," said Richard T. Schumacher, president and chief executive in a regulatory statement.

"We look forward to integrating NetworkNewsWire's strategies into our own as we focus on delivering an equitable return to our shareholders by increasing the exposure of our company and its potentially remarkable impact on the life sciences industry."

NNW is a financial news and publishing company, it said.

Its strategies help public and private organizations find their voice and build market visibility.

"Pressure BioSciences has developed a cutting-edge technology that has the potential to play a significant role in a number of commercially important areas," states Sherri Franklin, director of Content Marketing for NNW.

Last week it emerged that Pressure BioSciences was  to collaborate with Phasex Corporation to combine its  exciting ultra shear technology (UST) with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

The UST technology has recently been issued its first two patents in China.

Shares added 3.24% to US$4.14 each

]]>
Mon, 23 Oct 2017 09:02:00 -0400 https://www.proactiveinvestors.com/companies/news/186038/pressure-biosciences-hires-networknewswire-for-corporate-communications-186038.html
<![CDATA[News - Pressure BioSciences has high hopes for Phasex Corporation collaboration on UST tech ]]> https://www.proactiveinvestors.com/companies/news/185825/pressure-biosciences-has-high-hopes-for-phasex-corporation-collaboration-on-ust-tech-185825.html Pressure BioSciences Inc (OTCMKTS:PBIO) is to collaborate with Phasex Corporation to combine its  exciting ultra shear technology (UST) with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

As reported earlier this month, the UST technology was recently issued its first two patents in China.

"Following discussions with our colleagues at PBI, we believe the UST platform can be scaled to a cost-effective, commercially-viable level," Hans Schonemann, the president of Phasex, one of the world's most experienced supercritical fluid (SCF)-based toll processors.

"This would allow production of large quantities of stable, water-soluble nanoemulsions of compounds that were previously water-insoluble, such as CBD from cannabis.

"Such aqueous nanoemulsions could significantly increase the absorption and bioavailability of CBD and other previously water-insoluble compounds, which we believe would subsequently result in significant increases in their commercial demand."

Richard Schumacher, the chief executive and president at Pressure BioSciences, added: "We believe the ability to subject liquids to UST following the Phasex SCF extraction and purification process would be a highly sought-after "Value-add" for Phasex customers.

"Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies.

"Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration."

UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch).

]]>
Wed, 18 Oct 2017 11:20:00 -0400 https://www.proactiveinvestors.com/companies/news/185825/pressure-biosciences-has-high-hopes-for-phasex-corporation-collaboration-on-ust-tech-185825.html
<![CDATA[News - Pressure BioSciences' latest Barocycler machine's credentials featured at scientific meetings ]]> https://www.proactiveinvestors.com/companies/news/185364/pressure-biosciences-latest-barocycler-machine-s-credentials-featured-at-scientific-meetings-185364.html Pressure cycling technology (PCT) specialist Pressure BioSciences Inc (OTCMKTS:PBIO) says its recently released Barocycler 2320EXTREME instrument has received plaudits at several European scientific meetings - boosting its potential in the European biopharma markets.

The machine can process and analyse under pressure up to 16 samples simultaneously, potentially leading to the discovery of new drugs and treatments.

It is estimated that there are over 1bn FFPE (formalin-fixed, paraffin-embedded) tissue samples in the world, collected over a span of many decades," says Dr Nathan Lawrence, the vice president of marketing and sales at Pressure BioSciences.

"Complete clinical histories for such samples are often available, including such important data as disease progression and outcome, medications taken, and symptoms.

"More effective analyses of such samples, enabled by methods such as PCT, is expected to result in a bonanza of new and important biomarker discoveries. These discoveries open pivotal opportunities for development of new drugs, therapies, and disease-prevention strategies."

SCIEX, the co-marketing partner of PBI, organized an all-day seminar focused on the latest applications of mass spectrometry in digital biobanking in Munich, which discussed the Barocycler 2320EXT.

The 55th European High Pressure Research Group  took place in Poznan, Poland and looked at high pressure research.

The 16th Human Proteome Organization (HUPO) World Congress took place in Dublin, Ireland.

The OTCQB-listed firm develops and sells proprietary laboratory instrumentation and associated consumables to the US$6bn life sciences sample preparation market.

Shares added 3.24% to US$4.14 in New York.

]]>
Tue, 10 Oct 2017 12:09:00 -0400 https://www.proactiveinvestors.com/companies/news/185364/pressure-biosciences-latest-barocycler-machine-s-credentials-featured-at-scientific-meetings-185364.html
<![CDATA[News - Pressure BioSciences' chief upbeat on company's potential despite recent stock lows ]]> https://www.proactiveinvestors.com/companies/news/185360/pressure-biosciences-chief-upbeat-on-company-s-potential-despite-recent-stock-lows-185360.html Pressure BioSciences Inc (OTCMKTS:PBIO) chief Richard T. Schumacher is upbeat on the instrument developer's potential and says it has transformed from where it was nine years ago.

The chief executive recently conducted a podcast on the Uptick Network Stock Day, where he spoke about the firm's growing sales and its sales teams.

WATCH THE PODCAST HERE..

From having just one salesperson previously, he told presenter Everett Jolly: "We now have six sales people, we have a brand new award-winning instrument that is opening up doors and areas of biopharma companies, that we could never have got into before."

Last month the group revealed its  next-generation PCT (pressure cycling technology) instrument - the Barocycler 2320EXTREME -  had been selected as a finalist in the prestigious R&D 100 Awards for 2017.

"This company is at an all time high in its potential and its ability to succeed and bring back a great return on investment for investors, and yet we've been hitting our all-time lows in the  past month as a stock price," explained Schumacher.

"Our sales are increasing and our stock price is really not responding."

"We've already broken US$1mln in the first half of the year. In the third quarter, I've already given guidance that investors should expect a record number for our third quarter. Things aren't going down, things are actually moving up.." he added.

Earlier this month, Pressure BioSciences said it was very excited about the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.

The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.

The group is a pressure expert and UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch)

 "The company believes that UST has the potential to play a significant role in a number of commercially important areas, including the formulation of high quality stable nanoemulsions and the preparation of extended shelf-life "clean label" food," it told investors.

Shares in New York added 3.24% on the day to US$4.14 each.

]]>
Tue, 10 Oct 2017 10:49:00 -0400 https://www.proactiveinvestors.com/companies/news/185360/pressure-biosciences-chief-upbeat-on-company-s-potential-despite-recent-stock-lows-185360.html
<![CDATA[News - Pressure BioSciences reveals UItra Shear Technology patent news ]]> https://www.proactiveinvestors.com/companies/news/184935/pressure-biosciences-reveals-uitra-shear-technology-patent-news-184935.html Pressure BioSciences Inc (OTCMKTS:PBIO) is excited at the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.

The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.

READ - Pressure BioSciences' Barocycler instrument named finalist in 2017 R&D 100 awards READ THE BIG PIC - Pressure BioSciences' technology is building momentum

UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch)

"The company believes that UST has the potential to play a significant role in a number of commercially important areas, including the formulation of high quality stable nanoemulsions and the preparation of extended shelf-life "clean label" food," it told investors today.

One use is to make what's called nanoemulsions - mixtures of two or more liquids, which could be used in various medical products, pharmaceuticals, nutraceuticals, and cosmetics.

"Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels, and other advantages can be achieved with nanoemulsions when compared to standard macro- and micro-emulsions," the firm said.

Meanwhile, a number of clean label foods are currently processed using high-pressure treatments, including many juices, seafood, meats and fruits and vegetables.

In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at US$10 billion.

Dr Edmund Y. Ting, from Pressure BioSciences, who is a pioneer in the development of HPP and a co-inventor of UST, said: "HPP is very effective in reducing food-borne pathogens and extending shelf-life in pre-packaged foods (e.g., juices and ready-to-eat meats), thus eliminating the need for chemical additives."

He added: "UST uses ultra-high pressures to generate intense shear forces under controlled temperature conditions to produce nanoemulsions with significant reductions in food-borne pathogens, perhaps reaching sterilization. Evidence suggests that under such extreme conditions, even bacterial spores can be inactivated."

He said Pressure's initial focus will be to evaluate UST for the production of high-quality dairy products and beverages.

Shares eased 4.29% to US$4.02 each.

]]>
Mon, 02 Oct 2017 11:39:00 -0400 https://www.proactiveinvestors.com/companies/news/184935/pressure-biosciences-reveals-uitra-shear-technology-patent-news-184935.html
<![CDATA[News - Pressure Biosciences' Barocycler instrument named finalist in 2017 R&D 100 awards ]]> https://www.proactiveinvestors.com/companies/news/184162/pressure-biosciences-barocycler-instrument-named-finalist-in-2017-rd-100-awards-184162.html Pressure Biosciences Inc (OTCQB: PBIO), the life sciences sector sample preparation firm, said its  next-generation PCT (pressure cycling technology) instrument - the Barocycler 2320EXTREME -  was selected as a finalist in the prestigious R&D 100 Awards for 2017.

Finalists were chosen by an independent panel of more than 50 judges, based on each product's impact potential, uniqueness, and technical capabilities, said the firm.

This year's winners will be announced at a ceremony on November 17 this year.

ProCan, a cancer research initiative in Australia and the first international collaborator of the US Cancer Moonshot program, purchased three of the products last year

Professor Phil Robinson, co-director, said: "We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. The goal is to diagnose each individual patients' cancer to make more rapid and accurate predictions of the best cancer treatment to use -- or to avoid -- for that individual. This will also advance scientific discovery for new drug targets."

He added: "Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, a project like ProCan simply could not be done."

Shares added 3.24% to US$4.14

]]>
Mon, 18 Sep 2017 13:19:00 -0400 https://www.proactiveinvestors.com/companies/news/184162/pressure-biosciences-barocycler-instrument-named-finalist-in-2017-rd-100-awards-184162.html
<![CDATA[News - Pressure Biosciences eyes further revenue growth for 2017 after second quarter numbers ]]> https://www.proactiveinvestors.com/companies/news/182554/pressure-biosciences-eyes-further-revenue-growth-for-2017-after-second-quarter-numbers-182554.html Pressure Biosciences Inc (OTCMKTS:PBIO) continues to see quarter-on-quarter growth in total revenue, products and services revenue, and instrument sales, the firm said in its second quarter results.

However, the operating loss was widened in the three months to end June to $1.204mln from $1.060mon in the same period last year - an increase of 14% - largely due to increased sales and marketing expenses.

READ THE BIG PICTURE HERE - Pressure Biosciences' technology is building momentum READ - Pressure Biosciences delighted at collaborator's recognition

The company develops and sells proprietary laboratory instrumentation and associated consumables to the sample preparation market.

In April this year. Joseph L. Damasio joined the company as its chief financial officer. He said the second quarter had seen progress in several important areas.

Specifically, the firm, he said,  worked closely with contract manufacturer and raw materials vendors in an effort to reduce the costs of both the parts and assembly of our recently released, next generation Barocycler 2320EXTREME instrument.

The company also upgraded the systems and procedures used to analyze and track inventory, bill-of-materials, and costs-of-goods-sold.

Richard T. Schumacher, President and chief executive, added that it had hired a five-member field sales force.

"We expect all five sales directors to be fully trained and in the field between Labor Day and the end of September 2017," he said, expecting them to impact sales from the third quarter.

"...we made measurable progress on our goal to upgrade the software on our Barocycler 2320EXT to GMP/GLP-compliance, which we believe will open up a significant market opportunity for the 2320EXT in the drug design, development, validation, manufacture, and quality control of biological drugs...," he added

"....we announced for the first time that we have filed a patent for 'ultra-shear technology,' which we believe could address a significant, unmet need in both the biopharma and 'clean label' food areas."

Total revenue in the second quarter was $540,372 compared to $510,963 during the same period in 2016, an increase of 6%, mainly due to higher revenue from grant related activities and instrument sales.

Products and services revenue increased to $480,400, compared to $474,187 last year - an increase of 1%.

Net loss in the quarter was $583,760, compared to an income of $961,829 in the same period of 2016.

]]>
Wed, 16 Aug 2017 14:54:00 -0400 https://www.proactiveinvestors.com/companies/news/182554/pressure-biosciences-eyes-further-revenue-growth-for-2017-after-second-quarter-numbers-182554.html
<![CDATA[News - Pressure Biosciences delighted at collaborator's recognition ]]> https://www.proactiveinvestors.com/companies/news/178795/pressure-biosciences-delighted-at-collaborator-s-recognition-178795.html Pressure Biosciences Inc (OTCMKTS:PBIO), the lab instrumenation specialist, said collaborator Dr Ruedi Aebersold, has been recognised in a prestigious bioanalytics award scheme.

Aebersold received the Karger Medal from the Barnett Institute of Chemical & Biological Analysis in Boston, Masachusetts.

It recognizes an individual who has 'significantly contributed' to the development of new bioanalytical methods.

As part of the ceremony, Dr Aebersold presented two seminars, which highlighted his research in proteomics - the study of the entire set of proteins produced by healthy and diseased cells.

Both lectures included slides describing his use of Pressure BioSciences' novel, award winning, next-generation Barocycler 2320EXTREME for proteomic sample preparation in biomarker discovery and other research applications.

Quoting from the lectures, the firm said the doctor explained: "Not only do we need to consider the method of analyzing the proteome, we must also recognize that the method of sample preparation used for extraction and digestion of proteins is equally important to achieve a high degree of reproducibility of research results."

In 2015, Dr Aebersold and Dr Tiannan Guo collaborated with Pressure scientists and engineers to develop PCT-SWATH, a sample preparation and analysis method that combines the firm's sample preparation platform with SCIEX's SWATH-MS-based proteomics workflow.

PCT-SWATH is also notably employed by ProCan, a cancer research initiative at the Children's Medical Research Institute in Australia, which is also an NCI Cancer Moonshot collaborator.

Vice president of marketing and sales at Pressure BioSciences Dr Nate Lawrence, said: "We are delighted that Dr. Aebersold has again been recognized for his groundbreaking research in proteomics.

"We are honored to be both his colleague and collaborator in the development of instrumentation and methods essential in the preparation of samples for the discovery of protein biomarkers and other important applications.

"We look forward to working with Professor Aebersold and his team for years to come."

Shares in New York rose almost 6% to $6.99 each.

]]>
Mon, 05 Jun 2017 11:55:00 -0400 https://www.proactiveinvestors.com/companies/news/178795/pressure-biosciences-delighted-at-collaborator-s-recognition-178795.html
<![CDATA[News - Pressure BioSciences announces 1-for-30 stock consolidation ]]> https://www.proactiveinvestors.com/companies/news/178731/pressure-biosciences-announces-1-for-30-stock-consolidation-178731.html Pressure Biosciences Inc. ( OTCMKTS:PBIO ) has announced a one-for-thirty reverse split of its common stock to take effect next Monday.

The shares underlying the company's outstanding convertible securities will also be adjusted accordingly, the laboratory instruments designer told investors.

The reverse split will have the effect of reducing the number of shares each shareholder owns while at the same time increasing the value of each share, effectively leaving the value of each shareholder’s stake unchanged.

Once the reverse split - also known as a consolidation - has taken place, there will be around 1.06mln Pressure Bio shares in issue.

]]>
Fri, 02 Jun 2017 13:02:00 -0400 https://www.proactiveinvestors.com/companies/news/178731/pressure-biosciences-announces-1-for-30-stock-consolidation-178731.html
<![CDATA[News - Pressure Biosciences' solid growth expected to continue, says SeeThruEquity ]]> https://www.proactiveinvestors.com/companies/news/178274/pressure-biosciences-solid-growth-expected-to-continue-says-seethruequity-178274.html Reseach house SeeThruEquity issued an upbeat note on Pressure Biosciences Inc (OTCMKTS:PBIO) following its first quarter results.

The medtech and life sciences group began 2017 with nice growth, with revenues up 8% at $551,357 year-on-year, it said.

Business was particularly strong in the company's products and services segment, which demonstrated 16% annual growth led by strong instrument sales, noted SeeThruEquity.

"On its call with investors, PBIO management stated that it expected sales growth throughout the year as it expands distribution and selling partnerships, including the recently announced partnership with EKG Sales Associates; the company also expects an increase in grant revenues later in the year," it added.

A CE mark for Barocycler...

The research group also said that the firm had achieved its CE marking for its Barocycler 2320EXTREME sample instrument system faster than originally expected.

"The CE Marking is a significant milestone as it allows the Barocycler to be sold in Europe," it said.

"The company has announced that it is pursuing an uplisting to the Nasdaq, with a goal of completing the process by the end of 2Q17.

"We expect this move will require a transaction that will bring in much needed capital, but also affect shares outstanding, in order to meet minimum share price and shareholder's equity thresholds for a national listing," it added.

Last week, Joseph L. Damasio, chief financial officer, said: "As reported, we continued to show quarter-over-quarter revenue growth, especially in the important area of products and services.

"We also increased gross margins during the period. What makes these accomplishments even more rewarding was their achievement during a quarter in which we were also able to reduce operating expenses and operating loss."

]]>
Wed, 24 May 2017 10:41:00 -0400 https://www.proactiveinvestors.com/companies/news/178274/pressure-biosciences-solid-growth-expected-to-continue-says-seethruequity-178274.html
<![CDATA[News - Pressure Biosciences increases revenue and gross margins in first quarter ]]> https://www.proactiveinvestors.com/companies/news/177875/pressure-biosciences-increases-revenue-and-gross-margins-in-first-quarter-177875.html Sales of products and services helped boost revenues in the first quarter, said Pressure Biosciences Inc (OTCMKTS:BIO), positioning it well for growth in the rest of fiscal 2017.

The life sciences group develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn sample preparation market

READ - Pressure Biosciences names Damasio as finance chief as it travels towards profitability READ BIG PICTURE - Pressure Biosciences' technology is building momentum

Total revenue came in at $551,357 for the three months to March 31, compared to $510,478 during the same period of 2016, despite a decrease in grant revenue.

Products and services revenue increased 16% to $525,998, mainly due to a 19% increase in instrument systems sales.

Sales of consumables also increased 43% to $63,264 in the quarter.

The operating loss decreased 4% to $999,103 from $1,045,945 for the same quarter of 2016.

Joseph L. Damasio, chief financial officer, said: "As reported, we continued to show quarter-over-quarter revenue growth, especially in the important area of products and services.

"We also increased gross margins during the period. What makes these accomplishments even more rewarding was their achievement during a quarter in which we were also able to reduce operating expenses and operating loss.

"We believe the financial results of the first quarter 2017 have set us up well to significantly drive revenue and business growth for the rest of the fiscal 2017 year, and beyond."

Richard T. Schumacher, president and chief executive, added: "Although pleased with the financial results of the first quarter, we are even more pleased with our operational accomplishments."

Included in these, in February, it achieved CE Marking for its Barocycler 2320EXT, the next-generation PCT-based sample preparation instrument.

Pressure can now market and sell the device in all 31 countries in the European Economic Area.

Meanwhile, in March, it significantly bolstered its sales capabilities by contracting with lead generating firm EKG Sales Associates, and by hiring two of its planned four field sales directors.

Shares lost 5.82% on the day.. 

]]>
Tue, 16 May 2017 13:22:00 -0400 https://www.proactiveinvestors.com/companies/news/177875/pressure-biosciences-increases-revenue-and-gross-margins-in-first-quarter-177875.html
<![CDATA[News - Pressure Biosciences names Damasio as finance chief as it travels towards profitability ]]> https://www.proactiveinvestors.com/companies/news/176472/pressure-biosciences-names-damasio-as-finance-chief-as-it-travels-towards-profitability-176472.html Pressure Biosciences Inc (OTCQB:PBIO) has welcomed Joseph L Damasio back to the company as it ramps up, appointing him vice-president of finance and chief financial officer.

Damasio was employed at Pressure in 2007 as accounting manager, then as controller a year later and as vice president of finance and administration in 2011.

READ - Pressure Biosciences' technology is building momentum READ - Pressure BioSciences sets stage for "very successful" 2017

Most recently, the experienced executive was finance director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over $100mln in annual global sales.

Damasio told investors on Monday: "The company has developed and is beginning to implement a comprehensive fiscal plan that we believe is both achievable and sustainable, while supporting continued growth.

"Among its many goals, the plan calls for an up-list to the NASDAQ stock market, the addition of personnel in key areas, a strong focus in and expansion of sales and marketing, and a march towards profitability."

Pressure's president and chief executive Richard T. Schumacher added : "We are delighted to have Joe re-join the senior management team at PBI.

"During his five years away, Joe gained a wealth of knowledge and experience that we believe will help us significantly as we look to accelerate the company's growth on our path to profitability and long-term success. Welcome back, Joe."

Last month, the group bolstered its marketing and sales capabilities by contracting a well-regarded life sciences lead generation service and hiring two of four new field sales directors.

EKG Sales Associates (EKG) has spent over 20 years developing a contact database with over 50,000 scientists and other individuals from the life sciences area, some of whom are key decision makers.

As well as engaging EKG, PBI has also hired Ms Rajni Kareer who will be the sales director covering all of the west coast of the US.

The other new director, Nicholas Cobb, will cover upstate New York, northern New England, and all of eastern Canada.

Shares shed over 4% to US$0.31.

]]>
Mon, 17 Apr 2017 10:04:00 -0400 https://www.proactiveinvestors.com/companies/news/176472/pressure-biosciences-names-damasio-as-finance-chief-as-it-travels-towards-profitability-176472.html
<![CDATA[News - Pressure BioSciences expands sales capabilities with new hires ]]> https://www.proactiveinvestors.com/companies/news/175312/pressure-biosciences-expands-sales-capabilities-with-new-hires-175312.html Pressure Biosciences Inc  (OTCQB:PBIO) has bolstered its marketing and sales capabilities for 2017 by contracting a well-regarded life sciences lead generation service and hiring two of four new field sales directors.

EKG Sales Associates (EKG) has spent over 20 years developing a contact database with over 50,000 scientists and other individuals from the life sciences area, some of whom are key decision makers.

As well as engaging EKG, PBI has also hired Ms Rajni Kareer who will be the sales director covering all of the west coast of the US.

The other new director, Nicholas Cobb, will cover upstate New York, northern New England, and all of eastern Canada.

He will also have responsibility for field service throughout the US and Canada.

Both hires have a strong background in selling capital equipment to research laboratories, including spectrometers and HPLC equipment, as well as lab consumables.

Roxana McCloskey, director of marketing and sales for North America, said: "We are excited with the hires of EKG and our two new field sales directors, but there is still much to do to complete our plan to build a viable, experienced, and successful marketing and sales team at PBI.

"We are committed to the immediate hire of at least two additional field sales directors, one each for the mid-west and east coast regions."

Yesterday, the firm revealed that the growth in products and services sales helped it to post a 10% increase in revenue in the year just gone.

Total revenue for the year to end December came in at $1.97mln compared to $1.79 mln in the same period of 2015.

Products and services revenue was up 27% to $1.79mln in 2016 versus $1.409mln in 2015.

]]>
Thu, 23 Mar 2017 13:06:00 -0400 https://www.proactiveinvestors.com/companies/news/175312/pressure-biosciences-expands-sales-capabilities-with-new-hires-175312.html
<![CDATA[News - Pressure BioSciences sets stage for "very successful" 2017 ]]> https://www.proactiveinvestors.com/companies/news/175244/pressure-biosciences-sets-stage-for-very-successful-2017-175244.html Growth in products and services sales helped Pressure Biosciences Inc (OTCQB: PBIO) post a 10% increase in revenue in the year just gone.

Total revenue for the year to end December came in at $1.97mln compared to $1.79 mln in the same period of 2015.

Products and services revenue was up 27% to $1.79mln in 2016 versus $1.409mln in 2015.

The operating loss was $3.73mln compared to a loss of $3.56mln in 2015, due primarily to increases in R&D, Sales and Marketing, and IR expenses, off-set to a certain extent by an increase in Total revenue.

Pressure Biosciences Inc had a busy 2016 in which it made progress, it said. The biotech is developing and selling laboratory instrumentats and associated consumables to the estimated $6bn life sciences sample preparation market.

Last month, it achieved CE Marking for its sample preparation instrument  Barocycler 2320EXTREME, giving it the green light to sell the product in Europe.

President and chief executive Richard T. Schumacher said: "Our accomplishments over the past year have set the stage for what we believe will be a very successful 2017."

The group enters the new year with a stronger balance sheet; a broader product offering; an award-winning, next generation instrument; a larger customer base; and enhanced sales and marketing capability, he said.

The 2017 goals include:  an up-list to the NASDAQ stock market in the second quarter,  measureable progress in completing and implementing a sound roadmap toward financial self-sufficiency and future growth and prosperity,  continuing  sales and marketing capabilities, and reach into new countries, investigators, and fields-of-use; and a focus on sales.

Shares added 6% to 27 cents.

]]>
Wed, 22 Mar 2017 14:15:00 -0400 https://www.proactiveinvestors.com/companies/news/175244/pressure-biosciences-sets-stage-for-very-successful-2017-175244.html
<![CDATA[News - Pressure BioSciences hits the CE Mark with next-gen sample preparation instrument ]]> https://www.proactiveinvestors.com/companies/news/172582/pressure-biosciences-hits-the-ce-mark-with-next-gen-sample-preparation-instrument-172582.html Pressure BioSciences, Inc. (OTCQB: PBIO) shares advanced by 6% on Thursday after the company said it had achieved CE Marking for the Barocycler 2320EXTREME, the company's recently-released, next-generation PCT-based sample preparation instrument, and has the green light to sell in Europe.

A leader in the development and sale of broadly enabling, pressure cycling technology (PCT)-based sample preparation solutions to the worldwide life sciences industry, PBIO said the company is permitted to begin sales of the Barocycler 2320EXT in the European Economic Area.

Since 1985, achievement of CE Marking has been required for products in 24 different categories sold within the European Economic Area. Each product falls under one or more Directives, which determine the specific requirements the product must meet.

When the CE Mark is affixed to a product, it signifies the manufacturer's declaration that the product meets all applicable EU safety, health, or environmental requirements. Achieving CE Marking requires substantial cost, time, and effort from the manufacturer, but allows the product to be marketed and move freely throughout all 31 countries in the EEA that require the CE Mark.

The Barocycler 2320EXT is the most recent addition to, and the next generation of, PBI's Barocycler family. It is a compact, bench top instrument offering many features and benefits not found in PBI's earlier Barocycler models, such as data logging options, user-level security, computer-operated control with touch screen programming, and the ability to customize multiple pressure cycling parameters. These and other features have already positioned the Barocycler 2320EXT as an instrument of choice for life science key opinion leaders (KOLs) worldwide, when preparing protein samples for analysis.

Among these KOLs is Professor Ruedi Aebersold, a world-renowned protein chemist and Director of the Institute of Molecular Systems Biology in Zurich, Switzerland. Professor Aebersold has been a leading proponent of PBI's PCT-based sample preparation methods prior to proteomic analyses for some time.

"Achievement of CE Marking for the Barocycler 2320EXT is an important next step in our commercialization plans for this powerful and enabling sample preparation instrument, especially since CE Marking is required prior to selling the Barocycler 2320EXT to the large and potentially lucrative biopharmaceutical market in Europe,” said Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI

“We recently signed agreements with several strong distribution partners in Europe, our SCIEX co-marketing agreement is entering its second year (SCIEX is a global provider of laboratory instrumentation to the life sciences area, with a large presence in Europe), and Professor Ruedi Aebersold - one of the most recognized world leaders in proteomics - recently purchased two Barocycler 2320EXTs. We believe we are well prepared for our upcoming, planned launch of the CE Marked Barocycler 2320EXT in Europe. These are very exciting times for PBI."

BPIO shares were up 6.1% at $0.16 on Thursday.

]]>
Thu, 02 Feb 2017 12:58:00 -0500 https://www.proactiveinvestors.com/companies/news/172582/pressure-biosciences-hits-the-ce-mark-with-next-gen-sample-preparation-instrument-172582.html
<![CDATA[News - Pressure BioSciences to present at RedChip's Global Online Growth Conference ]]> https://www.proactiveinvestors.com/companies/news/172134/pressure-biosciences-to-present-at-redchip-s-global-online-growth-conference-172134.html Pressure Biosciences Inc (OTCMKTS:BIO) said on Tuesday Richard T. Schumacher, President and CEO, is scheduled to present at RedChip's Global Online Growth Conference on Wednesday January 25, 2017, at 11:30am EST.

The company is a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry.

]]>
Tue, 24 Jan 2017 15:10:00 -0500 https://www.proactiveinvestors.com/companies/news/172134/pressure-biosciences-to-present-at-redchip-s-global-online-growth-conference-172134.html
<![CDATA[News - Pressure BioSciences to present at the 2017 Biotech Showcase ]]> https://www.proactiveinvestors.com/companies/news/171423/pressure-biosciences-to-present-at-the-2017-biotech-showcase-171423.html Pressure Biosciences Inc (OTCMKTS:BIO) said on Tuesday Richard T. Schumacher, President and CEO, will present a corporate overview at the 9th Annual Biotech Showcase at 1700 PST later today.

The Biotech Showcase is being held January 9-11 at the Hilton San Francisco Union Square, San Francisco, CA.

Pressure Biosciences is a leader in the development and sale of broadly enabling, pressure cycling technology-based sample preparation solutions to the worldwide life sciences industry.

Pressure Biosciences Inc shares were up 2.6% at $0.18 on Tuesday.

]]>
Tue, 10 Jan 2017 13:54:00 -0500 https://www.proactiveinvestors.com/companies/news/171423/pressure-biosciences-to-present-at-the-2017-biotech-showcase-171423.html
<![CDATA[News - Pressure Biosciences' technology is building momentum ]]> https://www.proactiveinvestors.com/companies/news/171264/pressure-biosciences-technology-is-building-momentum-171264.html Pressure Biosciences Inc (OTCMKTS:BIO) has seen momentum building behind its proprietary technology  and it is primed for a successful fiscal 2017.

Revenues are on the rise and the group’s efforts to bring in new business is delivering.

The firm develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn sample preparation market.

The company got a major shot in the arm in December and now sees itself playing a key role in a new cancer research initiative in the United States, following the introduction of new legislation.

First quarter shows financial and operational success

Sales of products and services helped boost revenues in the first quarter. Total revenue came in at $551,357 for the three months to March 31, compared to $510,478 during the same period of 2016, despite the decrease in grant revenue.

Products and services revenue increased 16% to $525,998, mainly due to a 19% increase in instrument systems sales.

Sales of consumables also increased 43% to $63,264 in the quarter.

The operating loss decreased 4% to $999,103 from $1,045,945 for the same quarter of 2016.

A CE mark for preparation instrument

In February this year, it achieved a CE Marking for its sample preparation instrument  Barocycler 2320EXTREME, giving it the green light to sell the product in Europe.

It can now market and sell the device in all 31 countries in the European Economic Area.

Meanwhile, in March, it significantly bolstered its sales capabilities by contracting with lead generating firm EKG Sales Associates, and by hiring two of its planned four field sales directors.

And it has now welcomed back veteran financial executive Joseph L Damasio back to the company, appointing him vice-president of finance and chief financial officer.

Damasio was employed at Pressure in 2007 as accounting manager, then as controller a year later and as vice president of finance and administration in 2011.

A major role in a cancer moonshot

In December, 2016, the company told investors that it expects to play a key role in the US $1.8bn “Cancer Moonshot” initiative after legislation was signed.

Specifically, it is set to benefit from the 21st Century Cures Act which included $1.8bn earmarked specifically for cancer research.

Pressure BioSciences’ technology is already being featured as an essential technology and used by leading researchers participating in the ‘Cancer Moonshot’ and other important research programs.

This program aims to accelerate cancer research and support other avenues that will improve the ability to understand, prevent, detect, treat, and even cure cancer. Its goal is to try and achieve in the next five years what would normally take ten years to complete.

This will be achieved in part by increasing the number of cancer researchers and studies, increasing the sharing of samples and data among these researchers, and by offering cancer researchers access to 21st Century, cutting-edge laboratory tools (instruments, consumables, etc.) that will enhance and improve their research studies.

Proprietary technology and winning over opinion leaders

Pressure Biosciences’ proprietary PCT-HD system has in recent years been trialled and adopted by leading scientists.

“We have a unique, patented technology that is now beginning to be appreciated by scientists around the world,” Richard Schumacher, the group’s founder and chief executive said earlier this year.

Schumacher highlighted that generally the life sciences have moved on significantly in past decades with the focus increasingly upon the intricacies within cells rather than what occurs around the outsides of them.

However, he says the technological approach to actually ‘open’ cells remains relatively crude and are still largely the same as they were in the 1980s (when he was last in the lab in a scientific capacity).

At Pressure BioSciences we’ve developed this new method, never been used before, to open the cell and get “all the good stuff” out.

“Essentially it is like a sponge, we squeeze it out. Where others beat up ‘the sponge’ using mechanical, we put it in a pressure chamber. It is much gentler, it is much more controllable.”

Schumacher points out that, generally speaking, scientists are stubborn people by nature,  and convincing them to change their working practices has been one of the biggest challenges for the company.

But, by targeting what he calls ‘key opinion leaders’ in certain specialist fields Schumacher says Pressure Bioscience has started to overcome this hurdle.

“You have to go after the key opinion leaders. The scientists around the world that are recognised as the experts in studying proteins, DNA, RNA and lipids.

“We have to go after them and get them to use the technology with the assumption that once they’ve used it, they’ll realise how much better the system is. That’s what we’ve done."

]]>
Fri, 06 Jan 2017 08:36:00 -0500 https://www.proactiveinvestors.com/companies/news/171264/pressure-biosciences-technology-is-building-momentum-171264.html
<![CDATA[News - Pressure BioSciences,’ big role in $1.8bn "Cancer Moonshot" initiative ]]> https://www.proactiveinvestors.com/companies/news/170622/pressure-biosciences-big-role-in-18bn-cancer-moonshot-initiative-170622.html Pressure BioSciences, Inc. (OTCMKTS:PBIO) sees itself playing a key role in the US $1.8bn “Cancer Moonshot” initiative after legislation was signed this week, according to a statement on Friday.

A leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the large and growing worldwide life sciences industry, the company discussed the potential impact of the $6.3bn 21st Century Cures Act that was signed into law earlier this week.

The bill contains $1.8bn earmarked specifically for cancer research – the so-called Cancer Moonshot initiative.

The Company's PCT sample preparation system is already being featured as an essential technology and used by leading researchers participating in the Cancer Moonshot and other important research programs.

This program aims to accelerate cancer research and support other avenues that will improve the ability to understand, prevent, detect, treat, and even cure cancer. Its goal is to try and achieve in the next five years what would normally take ten years to complete. This will be achieved in part by increasing the number of cancer researchers and studies, increasing the sharing of samples and data among these researchers, and by offering cancer researchers access to 21st century, cutting-edge laboratory tools (instruments, consumables, etc.) that will enhance and improve their research studies.

"We believe strongly that discovery starts with sample preparation. Consequently, it is critical that cancer researchers have access to cutting-edge instruments, consumables, and other products that will give them the best chance of success, by giving them the best-in-class method or methods to prepare their samples prior to testing," said Dr. Nate Lawrence, Vice President of Marketing and Sales at PBI.

"We believe that, in many cases, the use of our PCT Sample Preparation System in protein analysis results in higher quality research data when compared to sample preparation with current technologies. This should result in a greater opportunity for discovery, which is one of the most important goals of the Cancer Moonshot initiative," he added.

The developments come just a month after the company reported bullish third quarter earnings. Read more.

]]>
Fri, 16 Dec 2016 14:18:00 -0500 https://www.proactiveinvestors.com/companies/news/170622/pressure-biosciences-big-role-in-18bn-cancer-moonshot-initiative-170622.html
<![CDATA[News - Pressure BioSciences hits record high quarterly product revenues ]]> https://www.proactiveinvestors.com/companies/news/169096/pressure-biosciences-hits-record-high-quarterly-product-revenues-169096.html Pressure BioSciences, Inc. (OTCMKTS:PBIO) product and services revenues picked up in the third quarter to a record high and touched above $500,000 for the first time in any quarter - while lower expenses helped lead to a lower operating loss, the company said on Wednesday.

In the three months ended Sept 30, revenue from products and services amounted to $500,949 compared with $481,452 in the same period of 2015.

This was a record high for products and services revenue in a quarter and marked the first time that products and services revenue exceeded half a million dollars in a financial quarter.

Revenue was driven primarily by the sale of instruments, which also set a record high with $383,789 for the quarter, compared to $340,084 (the previous record) for the same quarter of 2015.

“We expect grant revenue to begin to increase in the fourth quarter of 2016 and continue to increase into 2017. Total revenue decreased to $535,334 in the third quarter 2016 from $580,334 for the third quarter of 2015. This decrease was due to the decrease in grant revenue,” the company said in a statement.

Total operating costs and expenses fell to $987,141 versus $1.271mln a year earlier. The operating loss incurred was substantially down at $451,807 compared with $690,728 a year earlier.

“Although we continue to carefully control expenditures, this decrease in operating loss was primarily due to credits received from a professional service organization the Company no longer uses,” it said in the statement.

“We believe that had these credits not been received, operating loss for Q3 2016 would have been greater than the operating loss for Q3 2015, primarily because of discounts we offered to initial purchasers of our new next-generation Barocycler 2320EXTREME instrument, higher costs experienced in sales and marketing as we began to expand such capabilities, and costs associated with pursuing CE Marking for the new Barocycler 23230EXTREME. A CE Mark is required by dozens of countries in order to sell product in their country.”

]]>
Wed, 16 Nov 2016 14:34:00 -0500 https://www.proactiveinvestors.com/companies/news/169096/pressure-biosciences-hits-record-high-quarterly-product-revenues-169096.html
<![CDATA[News - Pressure BioSciences makes initial close in $2.5mln funding ]]> https://www.proactiveinvestors.com/companies/news/168956/pressure-biosciences-makes-initial-close-in-25mln-funding-168956.html Pressure Biosciences Inc (OTCMKTS:PBIO) on Monday announced the initial close of $610,000 in gross proceeds in a $2.5 mln private placement.

A leader in the development and sale of broadly enabling, pressure-based sample preparation solutions to the worldwide life sciences industry, led by their patented pressure cycling technology platform, the company said that three accredited investors participated in the financing.

All investments were made in cash and were received into escrow between August 29 and November 10. One or more additional closes in the financing are expected to occur in the near future.

The company issued 1,525,000 shares of restricted common stock at $0.40 per share and common stock purchase warrants exercisable into a total of 1,525,000 shares of restricted common stock at $0.50 per share.

There are no registration rights with respect to the shares of common stock or the shares underlying the common stock purchase warrants issued. The company received net proceeds of $512,750 after subtracting legal and placement agent fees related to the financing.

]]>
Mon, 14 Nov 2016 14:49:00 -0500 https://www.proactiveinvestors.com/companies/news/168956/pressure-biosciences-makes-initial-close-in-25mln-funding-168956.html
<![CDATA[News - Pressure BioSciences, Inc. closes $2mln Line-of-Credit ]]> https://www.proactiveinvestors.com/companies/news/168505/pressure-biosciences-inc-closes-2mln-line-of-credit-168505.html Pressure Biosciences Inc (OTCMKTS:PBIO) shares rose on Thursday after the company said it has closed a $2 million line-of-credit with an accredited investor.

A leader in the development and sale of broadly enabling constant pressure and pressure cycling technology ("PCT")-based sample preparation solutions to the large and growing worldwide life sciences industry, Pressure Bio said the investor on Oct 28 bought a Promissory Note worth $2mln payable on the earlier of October 28, 2017 (the maturity date) or on the seventh business day after the closing of a Qualified Offering.

On the same day, the company received its initial $250,000 advance linked to the Note and issued to the Investor a five-year Common Stock Purchase Warrant to purchase 625,000 shares of the Company's common stock ("Common Stock") at an exercise price equal to $0.40 per share.

Pressure BioSciences shares closed up 2.3% at $0.29 on Thursday.

]]>
Thu, 03 Nov 2016 16:55:00 -0400 https://www.proactiveinvestors.com/companies/news/168505/pressure-biosciences-inc-closes-2mln-line-of-credit-168505.html